This disclosure relates generally to medical fluid connectors, and specifically to medical fluid connectors for providing additives in medical fluid lines.
In healthcare settings where an intravenous (IV) catheter is inserted into a patient, there is an ever-present risk of microbial invasion into the catheter, which can lead to a catheter-related bloodstream infection (CRBSI) in the patient. There are many negative effects of CRBSI's, including serious health risks and increased costs for additional patient treatment. It is common practice in situations where the risk of contracting a CRBSI is particularly high, such as in long-term uses of central venous catheters, to utilize an anti-microbial lock procedure to provide a static anti-microbial solution in the catheter when fluid is not being transferring to or from the patient through the catheter.
Disclosed are embodiments of medical fluid connectors and/or fluid-modifying devices configured to receive, convey, and/or dispense medical liquid, methods of making the same, and methods of using the same. In some embodiments, the medical connector or fluid-modifying device can be structured to include an initial stage in which medical liquid is infused into the connector and at least a portion of the medical liquid (or all of the medical liquid) is dispensed out of the connector essentially unchanged. The medical connector or fluid-modifying device also can be structured to include a subsequent or final stage in which medical liquid is not infused into the connector and a volume of therapeutic liquid is dispensed out of the connector. In some embodiments, as illustrated, the connector or fluid-modifying device transitions automatically from the initial stage to the subsequent or final stage (e.g., without mechanical actuation or manipulation by a user of a switch or product setting or device configuration), such as by operation of fluid flow only and/or by one or more changes in a force propagated in or through a fluid. In some embodiments, the connector transitions from the initial stage to the subsequent stage by manual actuation by a user, such as by moving or changing a fluid pathway and/or opening a valve within or on the connector. The therapeutic liquid can include a portion of the volume of the medical liquid that was infused into the connector in the initial stage plus a therapeutic additive.
Some embodiments disclosed or claimed in this specification, or in any applications that claim priority to this specification, will overcome one or more of the identified shortcomings in the prior art. However, not all embodiments disclosed or claimed in this specification, or in any applications that claim priority to this specification, will overcome any or all of the identified shortcomings of the prior art, but can be useful for one or more other purposes.
Some embodiments disclosed herein pertain to medical connectors, fluid dispensers, and/or fluid modifiers. In some embodiments, the medical connectors include fluid modifiers that infuse a medical fluid with one or more additives, or permit the addition of one or more additives into a medical fluid, or modify a medical fluid in some other way, as the medical fluid passes through or is dispensed from the connector. In some embodiments, methods of making and/or using the disclosed connectors are provided. The following description provides context and examples, but should not be interpreted to limit the scope of the inventions covered by the claims that follow in this specification or in any other application that claims priority to this specification. No single component or collection of components is essential or indispensable. For example, some embodiments may not include a fluid modifier. Any feature, structure, component, material, step, or method that is described and/or illustrated in any embodiment in this specification can be used with or instead of any feature, structure, component, material, step, or method that is described and/or illustrated in any other embodiment in this specification. The relative sizes and dimensions of components shown in the drawings are not limiting if not present in a claim, but are intended to form part of the supporting disclosure in this specification when claimed.
While conventional procedures for achieving anti-microbial locks exist, those procedures are time-consuming, require the acquisition, storage, and use of multiple liquids, may be highly dependent on the techniques employed by healthcare providers for successful outcomes (subject to human error or variation), and may not deliver the anti-microbial solution in an effective dosage or in a useful timing sequence. Some embodiments disclosed herein address one or more of these issues and/or other issues that can occur when using a catheter or while performing a conventional antimicrobial lock method with conventional equipment. In some embodiments, a medical fluid connector configured to provide an additive (e.g., an antimicrobial compound, etc.) to the catheter as a locking solution is provided. In some embodiments, as a medical fluid is passed through the connector, an initial volume of the medical fluid is unchanged or substantially unchanged, having little or no additive added to it, such that there is no clinically significant effect. In some embodiments, after the initial volume of medical fluid passes through the medical connector, the connector is configured to then permit removal of or distribute or expel (automatically, in some devices) an additive-infused or otherwise modified or different portion of medical fluid out of the connector and into the catheter. In some embodiments, a delayed release of additive into the medical fluid locks the catheter without infusing any (or substantially any or any clinically significant amount) of the locking solution (e.g., the additive-infused medical fluid) into the patient. For example, the initial liquid volume can be sufficient to flush the liquid container within the catheter into the patient (e.g., at least about 5 mL, or at least about 3 mL, or at least about 2 mL, etc.), and the volume of additive-infused liquid can be approximately equal to or less than the volume of liquid that is inside of the catheter in communication with the patient's blood flow (e.g., less than or equal to about 5 ml, or less than or equal to about 3 mL, or less than or equal to about 2 mL, etc.), or approximately equal to or less than the volume of liquid that is configured to be inside of the portion of the patient's catheter that is outside of the patient.
As illustrated in
The main fluid pathway 108 and the secondary fluid pathway 110 can be separated by one or more physical barriers, or can constitute different portions of a single liquid flow being transported through the connector 100, or can represent a single liquid pathway in one or more different phases or configurations. In some embodiments, as shown, liquid that flows directly through the main fluid pathway 108, without deviating into the secondary fluid pathway 100, can be isolated or separated from the additive 112 or from a carrier, such as a matrix or substrate or other holder, of additive 112, during one or more phases, stages, or configurations of use. As illustrated, in some embodiments, the main fluid pathway 108 is essentially straight and/or is essentially co-linear or co-axial with the main central axis or longitude of the connector 200, while the secondary fluid pathway 110 can comprise at least a portion that is offset or spaced laterally from the main central axis or longitude of the connector 200, and/or non-parallel with the main central axis or longitude of the connector 200, and/or can include one or more turns or can follow a tortuous pathway through the connector 200. As shown, the secondary fluid pathway 110 can create more turbulence during fluid flow than the main fluid pathway 108, and/or can be configured to direct fluid through at least a portion of the secondary fluid pathway 110 in a direction that is different from or generally or completely opposite from the direction of fluid flow through the main fluid pathway 108. In situations where the main fluid pathway 108 and the secondary fluid pathway 110 are separated by one or more physical barriers, a first diversion region 111 can be a location or a structure where the pathways 108, 110 separate or are caused to separate; and a second diversion region 113 can be a location or a structure where the separate pathways 108, 110 recombine or are caused to recombine. In many embodiments, either or both of the first and second diversion regions 111, 113 are omitted. In some embodiments, as shown in
Any of these steps and/or structures can be omitted. For example, in some embodiments, the connector 100 can be configured to permit all of the liquid to flow through a fluid pathway that includes one or more additives (e.g., if the additive is provided in the main fluid pathway and there is no secondary fluid pathway). In some embodiments, the one or more additives can be antimicrobial additives. As also described elsewhere herein, any other type of one or more additives can be used for any other type of patient therapy, with or without one or more antimicrobial additives.
As illustrated, in some embodiments, the connector 100 can comprise a fluid modifier 116 to alter one or more qualities of the liquid flow through the connector 100, such as by modifying the direction or size or shape of the liquid pathway through the connector 100 (e.g., in the secondary fluid pathway 110 and/or in the main fluid pathway 108), and/or by modifying the composition of the liquid flowing through the connector 100, such as by adding one or more additives 112 to the liquid flowing through the connector 100. A fluid modifier 116 may perform a single function or multiple functions. For example, in some embodiments, the fluid modifier 116 can: (a) permit the secondary fluid pathway to temporarily increase in size or volume or length; and/or (b) the fluid modifier 116 can affect the timing or sequence of the passage of liquid through the secondary fluid pathway, such as by delaying the passage of liquid that enters and/or that travels through the secondary fluid pathway 110 as compared to the passage of liquid through the main fluid pathway 108 (e.g., liquid that passes by and/or does not travel through the secondary fluid pathway 110); and/or (c) the fluid modifier 116 can include a coating or a dusting or an impregnation or any other suitable application or placement or attachment of one or more additives on or in or underneath or covered by or surrounded by the fluid modifier 116 that can be dispersed from or by the fluid modifier 116 into the liquid passing through or around the fluid modifier 116 in a dosage, timing, and/or sequence that is clinically effective for a therapeutic use, such as for providing an anti-microbial lock.
For example, in some embodiments, the connector 100 can be configured to receive through the fluid inlet 102 a first medical liquid, such as saline or water or some other medical liquid, and to deliver out of the fluid outlet 104 a pre-determined initial volume of saline or water or some other medical liquid that has the same or essentially or substantially the same composition or the same or substantially the same clinical effect as the first medical liquid, and then subsequently to deliver out of the fluid outlet 104 a pre-determined secondary volume of a second medical liquid that is comprised of the first medical liquid plus a clinically significant concentration of one or more additives 112 that can be used to provide an effective therapy to a patient, such as an anti-microbial lock in a catheter line. Any other desired liquid delivery profile can be accomplished, such as an additional or alternative fluid delivery concentration or composition or sequence. For example, the first medical liquid can include a clinically significant concentration of one or more additives, followed by a second medical liquid that does not include a clinically significant concentration of one or more additives or that includes a different clinically significant concentration of one or more additives (e.g., if the main fluid pathway 108 and the secondary fluid pathway 110 both include one or more additives, or if there is an additional fluid pathway or if there are layers of additives positioned within the pathway); or a generally uniform concentration of one or more additives can be provided through substantially the entire period of infusion of liquid through the connector 100. In some embodiments, the fluid modifier 116 or the connector 100 does not include any additive 112, but may accomplish one or more other purposes, such as performing a delay in the delivery of fluid or a pre-determine liquid-delivery sequence.
In some embodiments, as also described elsewhere herein, the secondary pathway 110 can fill as a result of, for example, a threshold volume and/or threshold rate of liquid passing into and/or through the main fluid pathway 108.
In some embodiments, the connector 100 comprises one or more additional fluid pathways (not shown) that fill before or after or while the secondary fluid pathway fills or is filled. In some embodiments, as described elsewhere herein, the additional pathways can fill as a result of, for example, a specific (e.g., threshold) volume and/or rate of liquid passing through the main fluid pathway and/or as a result of a specific (e.g., threshold) volume and/or rate of liquid passing through or into the secondary fluid pathway. In some embodiments, using a multistage configuration allows multiple infusion profiles or infusion profiles with multiple stages or changes to be obtained. In some embodiments, multiple connectors can be used (e.g., connected) serially or in any other way to achieve any of various clinically significant infusion profiles.
In some embodiments, there can be a boundary 118 that is in contact with or surrounding either or both of the main fluid pathway 108 and the secondary fluid pathway 110 or that is positioned between the main fluid pathway 108 and the secondary fluid pathway 100. The boundary can be configured to move, thereby changing either or both of the volumes or path lengths of the main fluid pathway 108 and the secondary fluid pathway 110, such as in a generally inverse relationship. In some embodiments, one or more valves can be provided between the main fluid pathway 108 and the secondary fluid pathway 110. For example, either or both of diversion regions 111, 113 can comprise a valve for selectively permitting or impeding fluid flow from the fluid entry region 106 and/or into the fluid exit region 114. The valve can transition between open and closed positions manually by a user or automatically (e.g., based upon a quantity of fluid flow or volume or a change in fluid pressure, or in some other way). In some embodiments, the valve or valves are responsive to a certain volume or force achieved in the main fluid pathway and/or in the secondary fluid pathway. In some embodiments, the connector 100 is configured to provide a desired dosage or concentration of one or more additives after a pre-determined period of time or after a pre-determined volume of liquid has passed through the connector 100, and/or during a pre-determined period of time or while a pre-determined volume of liquid is passing through the connector, in the medical liquid that flows out of the fluid outlet 104 of the connector 100.
In some embodiments, the fluid modifier 116 can be omitted or can be configured to have no effect on the size, shape, and/or length of the fluid pathway. For example, in some embodiments, the size and/or length of the secondary fluid pathway 110 and the main fluid pathway 108 are both static, and/or the size and/or length of the secondary fluid pathway 110 can be greater than the main fluid pathway 108, thereby delaying the delivery of liquid through the secondary fluid pathway 110 as compared to the main fluid pathway 108. The secondary fluid pathway 110 can include one or more additives that can be dispersed into the liquid flowing through the connector 100, with or without a fluid modifier 116 to disperse the one or more additives into the liquid.
In some embodiments, the connector 100 is configured to deliver or to infuse a specific and/or adjustable volume of medical fluid with the additive. In some embodiments, as also described elsewhere herein, this volume is controllable depending on the length, volume, or other dimensions of the secondary fluid pathway 110. In some embodiments, the connector is configured to distribute sufficient additive-infused liquid to fill or substantially fill the catheter to which it is attached. In some embodiments, the connector is selected and/or configured to provide a volume of additive-infused liquid that fills only a portion of the catheter (e.g., a portion of tubing external to the patient's body) and/or a volume insufficient to overflow out of the catheter into the patient. For example, the volume of additive-infused liquid to be emitted from the connector 100 can be configured to be less than or approximately equal to the interior fluid-carrying volume of the patient's catheter or less than or approximately equal to a portion of the patient's catheter that is configured to be positioned outside of the patient's body during use. In some embodiments, the volume of additive-infused liquid is less than or equal to about: 0.25 mL, 0.5 mL, 2 mL, 5 mL, 10 mL, 25 mL, values between the aforementioned values, ranges spanning those values, or otherwise. In some configurations, the connector can be configured to receive a volume sufficient to fill or overfill the catheter and/or to deliver a small amount of additive or the entire volume of additive infused liquid into the patient (e.g., when the additive is a medicament, etc.). In some embodiments, in a multistage configuration or other configuration, a volume of additive-infused liquid can be delivered from the connector, followed by an additive-free (or substantially additive-free) volume of medical fluid. In some embodiments, for example, where a therapeutic agent and locking agent are provided in a connector (or a series of connectors), the connector (or series) can be configured to deliver the therapeutic additive into the patient completely and to lock the catheter with the locking agent, which is retained or substantially retained in the catheter.
In some embodiments, the connector is configured to achieve one or more of the above-referenced volume distributions to the catheter when using any commercial catheter, including those selected from the group consisting of Hickman, Broviac, or Leonard tunneled catheters, including at least about 9 Fr or at least about 10 Fr Single or Double Lumen catheters, Double or Triple (e.g., red, blue, or white) Lumen catheters, at least about 12 Fr Double Lumen catheters, or at least about 12.5 Triple Lumen catheters. In some embodiments, the volume of additive-infused medical fluid distributed from (e.g., delivered out of) the connector is greater than or equal to about: 0.25 mL, 0.5 mL, 2 mL, 5 mL, values between the aforementioned values, ranges spanning those values, or otherwise. In some embodiments, the volume of additive-free medical fluid distributed from (e.g., delivered out of) the connector is greater than or equal to about: 0.25 mL, 0.5 mL, 2 mL, 5 mL, 10 mL, 25 mL, values between the aforementioned values, ranges spanning those values, or otherwise.
As also described in detail elsewhere herein, in some embodiments, at or near the termination of an infusion of medical liquid into the patient through the connector 100 (e.g., approximately at the point that the volume to be injected is achieved, the volume at which a plunger of a syringe used to infuse the fluid nears or reaches the terminal end of a syringe or bottoms out, at a point where the infusion is halted, etc.), the medical liquid in the secondary fluid pathway 110 exits the secondary fluid pathway 110 and passes through the fluid outlet 104. In some embodiments, this distribution of liquid from the secondary fluid pathway occurs automatically and/or without active manipulation of the connector by the user. In some embodiments, the medical fluid (e.g., the medical liquid without additive) and the additive-containing fluid (e.g., additive-infused liquid) mix at a location and/or time near or substantially at the end of the infusion of medical liquid through the connector 100 and/or form a locking solution at the fluid exit region 114 of the connector 100.
It is contemplated that any other embodiment that follows can include any feature, structure, component, material, step, or method of the connector 100 of
As illustrated in
For brevity, not every feature of the connector 200A of
As illustrated in
As shown in
As shown in
In some embodiments, as shown in
In some embodiments, the connector has a length measured generally from a first end (e.g., from the inlet 102) to a second end (e.g., to the outlet 104) along the direction of fluid flow. In some embodiments, the connector also has a diameter measured across the connector transverse to the direction of fluid flow from a first side of the connector to a second side laterally (e.g., extending radially outward from the fluid pathway). In some embodiments, this diameter of the connector can be greater than an outer diameter of the fluid inlet and/or the fluid outlet. In some embodiments, this diameter can improve ease of gripping of the connector between fingers of a user.
As shown in
In some embodiments, as also described elsewhere herein, having a length greater than the width of the connector also allows the user to easily grasp the connector and align it with the catheter during placement, replacement, or manipulation of the connector. In some embodiments, having a diameter greater than or equal to the length facilitates bulk storage and/or transport of the connectors. For example, as also described elsewhere herein, the connectors can be connected serially and stored or used (e.g., to infuse more than one additive or to infuse a greater quantity of additive). In some embodiments, in configurations where the diameter is greater than or equal to the length of the connector, serial or parallel connection and disconnection of the connectors is facilitated because the lateral sides of the connector protrude from the inlet and outlet portions of the connector, allowing easier access to and manipulation of individual connectors.
As shown in
As shown in
In some embodiments, the flexible carrier can be placed in an orientation that allows it to deform towards different portions of the connector 200, 200A, 200B, 200C, 200D. For example, in the embodiments of
In some embodiments, such as shown in the embodiments of
In some embodiments, such as shown in the embodiment of
As illustrated, in some embodiments, the first diversion region 111 of the embodiment of
As shown in
As shown in
The opening in the diverter or divider 246C can have a greater cross-sectional area than the lateral fluid region 252C. In some embodiments, the cross-sectional area of the opening in the diverter or divider 246C can be about four times that of the lateral fluid region 252C. In some embodiments, the opening in the diverter or divider 246C can have a greater internal diameter or width than the lateral fluid region 252C. In some embodiments, the internal diameter of the opening in the diverter or divider 246C can be at least about two times that of the lateral fluid region 252C. In some embodiments, the internal diameter of the opening in the diverter or divider 246C can be about 0.032″ and the internal diameter of the lateral fluid region 252C can be about 0.016″.
As shown in
The lateral fluid region 252D can have a generally uniform cross-section. As shown in
In some embodiments, such as shown in
In some embodiments, the connector comprises a fluid pathway with at least a portion that has a completely or at least substantially unobstructed pathway (e.g., through the entirety of the connector). For instance, while the constriction or diverter or divider 246, 246A, 246B, 246C, 246D can divert a portion of the medical fluid from the primary fluid path, a portion of fluid can travel directly through the opening in the diverter or divider or constriction unimpeded 266 (or 266C, 266D), 266B (as shown in
As shown in
The flexible carrier 232, 232A, 232B, 232C, 232D can be configured to carry one or more additives 112 and to transfer the one or more additives 112 into the liquid that flows around or contacts the flexible carrier 232, 232A, 232B, 232C, 232D. In some embodiments, the one or more additives 112 can comprise any one or more of the following: an antimicrobial, an antibiotic, an antiseptic, an analgesic, an anesthetic, a blood-thinner, a chemotherapy drug, an immunosuppressive drug, a nutritional supplement, or any other therapeutic substance that is combinable with a liquid flowing through the connector 200, 200A, 200B, 200C, 200D. An example of an antimicrobial additive is chlorhexidine gluconate, which can be provided in powdered form and coated or dusted or positioned or otherwise placed around the outer surface of the exterior wall 264, 264A, 264B, 264C, 264D of the flexible carrier 232, 232A, 232B, 232C, 232D. In some embodiments, the one or more additives 112 can be temporarily adhered or bound or attached to the exterior wall 264, 264A, 264B, 264C, 264D of the flexible carrier 232, 232A, 232B, 232C, 232D, such as by electrostatic forces or in surface recesses or by a water-soluble or saline-soluble binder, such as glycerol. In some embodiments, the one or more additives 112 can be formed or trapped or bound to or into the structure of the exterior wall 264, 264A, 264B, 264C, 264D of the flexible carrier 232, 232A, 232B, 232C, 232D such as by being captured within a cross-linked matrix of the exterior wall 264, 264A, 264B, 264C, 264D in a manner that permits leaching out or eluting of the one or more additives into the liquid as the liquid flows around or through the flexible carrier.
In some embodiments, a degradable (e.g., biodegradable, water dissolvable, etc.) matrix is deposited on the exterior wall 264, 264A, 264B, 264C, 264D and/or on the flexible carrier 232, 232A, 232B, 232C, 232D. In some embodiments, the flexible carrier 232, 232A, 232B, 232C, 232D is a degradable matrix. In some embodiments, a portion of the degradable matrix dissolves upon exposure to medical fluid. In some embodiments, as the matrix degrades, sufficient additive is released into the medical fluid to permit locking of the catheter. In some embodiments, the degradable matrix can have a tailored or adjustable degradation rate and/or additive concentration such that the degradation rate and/or delivery concentration is sufficient to deliver an appropriate locking concentration throughout the estimated lifetime of the catheter or the connector. For example, if a catheter is estimated to require locking about 15 times over its lifetime, the flexible carrier 232, 232A, 232B, 232C, 232D can be tailored to allow 1, 2, 10, 15 or more locks of the catheter line with sufficient therapeutic agent to, for example, avoid microbial growth in the catheter during the average lifetime use of the catheter.
In some embodiments, the additive (e.g. as disposed in, around, or near the variable-volume fluid-modifying region 254, 254A, 254B, 254C, 254D or elsewhere in the connector) comprises antibiotic. In some embodiments, the antibiotic is a gram-positive antibacterial, a gram negative antibacterial, or a combination thereof. In some embodiments, the additive comprises one or more of chlorhexidine, chlorhexidine gluconate, vancomycin, cefazolin, ceftazidime, ciprofloxacin, gentamicin, and/or ampicillin.
In some embodiments, the additive comprises an anti-coagulant. In some embodiments, the anti-coagulent is heparin. The anti-coagulant can be provided as the only additive or as an additive in combination with other additives described elsewhere herein. In some embodiments, the anti-coagulant is provided at a concentration of at least about: 100 units/mL, 2500 units/mL, 5000 units/mL, values between the aforementioned values, ranges spanning those values, or otherwise.
In some embodiments, the connector is configured to provide an additive infused solution with a concentration of equal to or at least about 0.2 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.5 mg/mL, 5.0 mg/mL, 10 mg/mL, values between the aforementioned values, ranges spanning those values, or otherwise.
As illustrated in
As shown in
Some of the medical liquid 266, 266C, 266D, 266B passes from the transitional region 274, 274D, 274B directly through the constriction or opening in the diverter or divider 246, 246D, 246B, or from the internal fluid pathway 226C directly through the opening in the diverter or diverter 246C, into the interior of the male protrusion 205, 205C, 205D, 205B. In some embodiments, as illustrated, the portion of the medical liquid 266, 266C, 266D, 266B that passes directly through can be essentially unchanged; that is, it can have the same or essentially the same composition as before it entered the connector 200, 200C, 200D, 200B, and/or it can be therapeutically or clinically the same (e.g., the medical liquid can have no concentration of additive or clinically insignificant concentration, which can be a low enough concentration of additive dissolved in the medical liquid such that the medical fluid can be infused directly into a patient or otherwise be used as though it were completely additive-free). This essentially unchanged medical liquid 266, 266C, 266D, 266B passes very quickly through the connector 200, 200C, 200D, 200B, without a clinically significant delay, and emerges from and continues to be emitted from the second fluid-line attachment 204, 204C, 204D, 204B during an initial time period or over a period during which an initial volume of liquid is dispensed from the connector 200, 200C, 200D, 200B.
Generally simultaneously, another portion of the medical liquid 266, 266C, 266D, 266B is diverted laterally because the opening in the diverter or divider 246, 246C, 246D, 246B creates a lower flow rate (volume/time) of medical liquid 266, 266C, 266D, 266B entering from the wider internal fluid pathway 226, 226C, 226D, 226B of the fluid guide 224, 224C, 224D, 224B (and the transitional region 274, 274D, 274B) into the opening in the diverter or divider 246, 246C, 246D, 246B. As described above, the transitional region 274, 274D, 274B in
In some embodiments, the diverted or laterally flowing liquid 276, 276C, 276D, 276B moves into the variable-volume fluid-modifying region 254, 254C, 254D, 254B and begins to: (a) exert a modifying force on the flexible carrier 232, 232C, 232D, 232B; and/or (b) contacts the exterior wall 264, 264C, 264D, 264B of the flexible carrier 232, 232C, 232D, 232B. In some embodiments of the connector 200, 200C, 200D, 200B, where the fluid modifier 116 is a flexible member but not a flexible carrier 232, 232C, 232D, 232B (e.g., because the fluid modifier 116 does not carry an additive 112), the variable-volume fluid-modifying region 254, 254C, 254D, 254B can contain the additive 112 or some other region or structure of the connector 200, 200C, 200D, 200B can contain or hold the additive 112 (e.g., a portion of a fluid-contacting inner wall 268, 268C, 268D, 268B of the housing 220, 200C, 200D, 220B or a portion of the fluid guide 224, 224C, 224D, 224B or one or more of any other structures or components of the connector 200, 200C, 200D, 200B, or any combination of structures or components). In some embodiments, the additive 112 can be omitted.
As shown in
As illustrated, in some embodiments, the movement of the flexible carrier 232, 232B can create a void between the exterior wall 264, 264B of the flexible carrier 232, 232B and the interior wall 268, 268B of the connector 200, 200B, which can increase the size of the variable-volume fluid-modifying region 254, 254B and temporarily store or retain liquid within the increasingly large fluid-modifying region 254, 254B. Once the flexible carrier 232, 232B begins to deform, it exerts a restoring force in opposition to the force of the entering liquid. In some embodiments, the force of the entering liquid is greater than the restoring force of the flexible carrier 232, 232B during the infusion stage. Simultaneously, the liquid in the fluid-modifying region 254, 254B can come into contact with and mix with one or more additives 112 on the flexible carrier 232, 232B or otherwise, transforming the liquid into a therapeutic liquid 278, 278B (e.g., an additive-containing liquid). In some embodiments, the therapeutic liquid 278, 278B can flow or swirl generally circumferentially around the interior of the housing 220, 220B of the connector 200, 220B in a general vortex pathway as medical liquid is infused into the connector 200, 200B, between the interior wall 268, 268B of the housing 220, 220B and the exterior wall 264, 264B of the flexible carrier 232, 232B, providing thorough mixing and consistency of concentration of additive 112 in the therapeutic liquid 278, 278B.
As shown in
As illustrated in
Any of the first or second or third or other stages can be combined or eliminated. Any steps or methods that are described and/or illustrated in any particular stage can be performed additionally or alternatively in another stage. The descriptions and/or illustrations of stages are not intended to be exhaustive or limiting. In some embodiments, as illustrated, any transition from any stage to any other stage can be automatic. For example, one or more transitions between any stages can be governed by fluid-flow and/or fluid pressure parameters, not by one or more intentional or direct user adjustments or modifications of the connector. In some embodiments, one or more connector features can be manipulated and used collectively and/or singularly to adjust and/or manipulate the ratio of medical fluid that remains substantially additive-free versus the amount of medical fluid infused with an additive (or additives). In some embodiments, multiple connector types with various features can be mixed and matched and attached serially for the infusion of multiple additives and/or to achieve multiple infusion profiles. As shown, in some embodiments, any of the connectors 200, 200A, 200B, 200C, 200D can be different from long-term medical pumps (e.g., bladder pumps or ambulatory pumps) in that the fluid-flow emitted from the downstream or outflow end or region of the connectors 200, 200A, 200B, 200C, 200D can terminate or stop generally simultaneously with or shortly after the fluid-flow infused or inserted into the upstream or inflow end or region of the connectors 200, 200A, 200B, 200C, 200D. For example, in some embodiments, as illustrated, the time between the beginning of fluid-flow infused or inserted into the upstream or inflow end or region of the connectors 200, 200A, 200B, 200C, 200D and the end of fluid-flow infused or inserted into the upstream or inflow end or region of the connectors 200, 200A, 200B, 200C, 200D can be generally equal to or greater than the time between the end of fluid-flow infused or inserted into the upstream or inflow end or region of the connectors 200, 200A, 200B, 200C, 200D and the end of fluid-flow emitted from the downstream or outflow end or region of the connectors 200, 200A, 200B, 200C, 200D, such that the connectors 200, 200A, 200B, 200C, 200D do not provide a long-term pumping function. Of course, in some embodiments, one or more structures, methods, functions, and/or components that are illustrated in the accompanying figures and/or described anywhere in this specification can be used in or with medical pumps or can be used as medical pumps with appropriate modifications.
In some embodiments, the cross-sectional area (e.g., diameter) of the internal fluid pathway is larger than the cross-sectional area of the fluid pathway through (or the opening in) the constriction or diverter or divider. In some embodiments, the diverter or divider can be a constriction. In some embodiments, the ratio of the cross-sectional area of the internal fluid pathway 226, 226A, 226B, 226C, 226D and the cross-sectional area of the opening in the diverter or divider or constriction 246, 246A, 246B, 246C, 246D can be changed from connector to connector to divert more or less liquid into the fluid modifying region. For example, if only a small volume of liquid is being infused, it may be advantageous to divert a larger volume of liquid into the fluid modifying region to allow sufficient additive to be infused into the medical fluid. As the cross-sectional area of the internal fluid pathway becomes larger relative to the cross-sectional area of the fluid pathway at the diverter or divider or constriction, more fluid pressure builds at the diverter or divider or constriction diverting more fluid into the fluid modifying region. In some embodiments, the ratio of a cross-sectional area of the internal fluid pathway to the cross-sectional area of the fluid pathway through the diverter or divider or constriction is equal to or less than about: 5:4, 4:3, 2:1, 5:1, values between the aforementioned ratios, ranges spanning those ratios, or otherwise.
Alternatively or additionally, in some embodiments, the cross-sectional area of the entrance (e.g., the lateral fluid region) to the fluid modifying region is larger than the cross-sectional area of the fluid pathway through the diverter or divider or constriction. In some embodiments, the ratio of the cross-sectional area of the entrance of the fluid modifying region to the cross-sectional area of the opening in the diverter or divider or constriction can be different among a plurality of connectors to divert more or less liquid into the fluid modifying region, depending upon clinical needs. When the cross-sectional area of the entrance to the fluid modifying region is larger than the cross-sectional area of the fluid pathway at the diverter or divider or constriction, more fluid can be diverted into the fluid modifying region. In some embodiments, the ratio of a cross-sectional area of the entrance to fluid modifying region to the cross-sectional area of the fluid pathway through the diverter or divider or constriction is equal to or less than about: 2:1, 5:1, 10:1 values between the aforementioned ratios, ranges spanning those ratios, or otherwise.
In some embodiments, the volume of the secondary pathway can be adjusted and/or the volume of the primary fluid pathway can be adjusted. In some embodiments, the capacity of the secondary fluid pathway (e.g., the volume of liquid the secondary pathway can hold when filled) is equal to or at least about: 0.125 mL, 0.25 mL, 0.5 mL, 2 mL, 5 mL, values between the aforementioned values, ranges spanning those values, or otherwise. In some embodiments, capacity of the primary fluid pathway is equal to or at least about: 0.1 mL, 0.2 mL, 0.5 mL, 1 mL, values between the aforementioned values, ranges spanning those values, or otherwise. In some embodiments, by making the volume of the secondary fluid pathway 110 larger than the volume of the main fluid pathway 108, a larger volume of additive-infused medical liquid can be infused into the catheter. As shown in
In some embodiments, as discussed elsewhere herein, the medical fluid can enter the secondary fluid pathway 110 (or an additional fluid pathway) based in part on the rate and/or the volume of medical fluid injected into the connector 100. In some embodiments, for example, the amount of deformation of the flexible carrier and/or the amount of fluid that enters the secondary pathway depends on the rate at which a fluid is passed through main fluid pathway of the connector. In some embodiments, the secondary fluid pathway 110 is filled with medical fluid and/or the flexible carrier deforms when an infusion from, for example, a syringe into the connector reaches a rate of equal to, or at least, about: 0.25 mL/sec, 0.5 mL/sec, 2 mL/sec, 5 mL/sec, values between the aforementioned values, ranges spanning those values, or otherwise. In some embodiments, the additive can be completely or substantially distributed into the medical fluid with an infusion rate from a syringe (or other infusion device) of equal to, or at least, about: 0.25 mL/sec, 0.5 mL/sec, 2 mL/sec, 5 mL/sec, values between the aforementioned values, ranges spanning those values, or otherwise.
In some embodiments, the amount of deformation of the flexible carrier and/or the amount of fluid that enters the secondary pathway depends on the volume of fluid that is passed through the connector. In some embodiments, the secondary fluid pathway 110 is filled with medical fluid when an infusion volume is equal to or at least about: 2.5 mL, 5 mL, 10 mL, values between the aforementioned values, ranges spanning those values, or otherwise. In some embodiments, the additive can be completely or substantially completely distributed into the medical fluid using an infusion volume of equal to or at least about: 2.5 mL, 5 mL, 10 mL, values between the aforementioned values, ranges spanning those values, or otherwise.
In some embodiments, the resiliency and/or the modulus of the flexible carrier can be selected to provide different release characteristics. In some embodiments, stiff materials deform less and result in less additive being added to the medical fluid but can expel the additive at a greater pressure and in less time. In some embodiments, the resilience of the flexible carrier is at least about: 0.1 J/m3, 1 J/m3, 10 J/m3, 100 J/m3, values between the aforementioned values, ranges spanning those values, or otherwise. In some embodiments, the modulus of the flexible carrier is greater than or equal to about: 0.01 GPa, 0.1 GPa, 1 GPa, 2 GPa, values between the aforementioned values, ranges spanning those values, or otherwise.
In some embodiments, a portion of the flexible carrier can comprise an indicator, for instance, a colored, luminescent, or fluorescent dye (not shown). In some embodiments, the indicator dissolves into the medical fluid with the additive. In some embodiments, the indicator is located on a portion of the flexible carrier that is away from or distal to the transitional region so that the indicator is only infused into the medical fluid after all or substantially all the additive is infused into the medical fluid. In some embodiments, where the indicator is present, the indicator only enters into the medical fluid when an appropriate rate and/or volume of medical fluid enters the variable-volume fluid-modifying region 254, 254A, 254B, 254C, 254D. In some embodiments, the indicator can be used to visually demonstrate that the additive has been appropriately infused into the medical fluid. In some embodiments, the indicator may also be used to visualize the distance that the lock solution (or any other therapeutic solution) has traveled in the catheter line.
In some embodiments, as shown in at least
Some embodiments pertain to methods of using medical fluid connectors as disclosed herein. Any device or structure illustrated or described in this specification can be used with any method in this specification. In some embodiments, a method includes the step of obtaining a connector. In some embodiments, a method includes the step of attaching the connector to a catheter. In some embodiments, a method includes the step of obtaining a syringe or device capable of holding a medical fluid. In some embodiments, a method includes the step of attaching the syringe or other device to the connector. In some embodiments, a method includes the step of introducing medical fluid into the connector and/or the catheter using the syringe or other medical fluid carrying device. In some embodiments, a method includes the step of introducing an additive to the fluid as it passes through the connector. In some embodiments, a first portion of fluid that is substantially additive-free is introduced to the catheter. In some embodiments, a second portion of fluid that contains additive is introduced to the catheter. In some embodiments, a first portion of fluid that contains additive (e.g., a therapeutic) is introduced to the catheter and/or passed through the catheter to the patient. In some embodiments, a second portion of fluid that is contains additive is introduced to the catheter. In some embodiments, the method includes the step of locking the catheter with an antimicrobial-containing medical fluid.
Some embodiments pertain to methods of preparing medical fluid connectors. In some embodiments, a method includes the step of obtaining one or more of a fluid guide, a proximal cover region (e.g., with a vent), and/or a distal fluid port. In some embodiments, a method includes the step of attaching a fluid modifier in place at a plurality of points or regions inside of the connector. In some embodiments, a method includes the step of affixing a proximal edge of the flexible carrier securely between an upper region (e.g., forming a lip, a projection, a barb, etc.) of the housing and an underside of the outer edge of a region of the fluid guide (e.g., a cover region). In some embodiments, a distal end region of the flexible carrier is fastened circumferentially (e.g., securely and/or in a fluid-tight manner) at the distal attachment region of the fluid guide, such as by affixing a distal opening in the flexible carrier that is slightly smaller than the outer circumference of the distal attachment region, causing the distal opening to exert a radially inwardly directed restoring force which tightly grips the distal attachment region of the fluid guide. In some embodiments, the fluid guide and/or the flexible carrier can be placed into the housing of the connector. In some embodiments, a cap can be placed over the fluid guide, securing it in place. In some embodiments, a first fluid line attachment can be affixed or placed on the fluid guide.
Certain features that are described in this disclosure in the context of separate implementations can also be implemented in combination in a single implementation. Conversely, various features that are described in the context of a single implementation also can be implemented in multiple implementations separately or in any suitable subcombination. Moreover, although features may be described above as acting in certain combinations, one or more features from a claimed combination can in some cases be excised from the combination, and the combination may be claimed as a subcombination or variation of a sub combination.
Any portion of any of the steps, processes, structures, and/or devices disclosed or illustrated in one embodiment, flowchart, or example in this disclosure can be combined or used with (or instead of) any other portion of any of the steps, processes, structures, and/or devices disclosed or illustrated in a different embodiment, flowchart, or example. The embodiments and examples described herein are not intended to be discrete and separate from each other. Combinations, variations, and other implementations of the disclosed features are within the scope of this disclosure.
Some embodiments have been described in connection with the accompanying drawings. Moreover, while operations may be depicted in the drawings or described in the specification in a particular order, such operations need not be performed in the particular order shown or in sequential order, and/or one or more of the operations may be omitted entirely, to achieve desirable results. Other operations that are not depicted or described can be incorporated in the example methods and processes. For example, one or more additional operations can be performed before, after, simultaneously, or between any of the described operations. Additionally, the operations may be rearranged or reordered in other implementations. Also, the separation of various components in the implementations described above should not be understood as requiring such separation in all implementations, and it should be understood that the described components and systems can generally be integrated together in a single product or packaged into multiple products. Additionally, other implementations are within the scope of this disclosure.
This application claims the benefit under 35 U.S.C. § 120 and 35 U.S.C. § 365(c) as a continuation of International Application No. PCT/US2018/030015, designating the United States, with an international filing date of Apr. 27, 2018, titled “MEDICAL FLUID CONNECTORS AND METHODS FOR PROVIDING ADDITIVES IN MEDICAL FLUID LINES,” which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 62/492,887, filed on May 1, 2017, U.S. Provisional Patent Application No. 62/520,300, filed on Jun. 15, 2017, U.S. Provisional Patent Application No. 62/558,618, filed on Sep. 14, 2017, and U.S. Provisional Patent Application No. 62/662,149, filed on Apr. 24, 2018, which are hereby incorporated by reference herein in their entireties, forming part of the present disclosure. Any feature, structure, material, method, or step that is described and/or illustrated in any embodiment in any of the foregoing provisional patent applications can be used with or instead of any feature, structure, material, method, or step that is described and/or illustrated in the following paragraphs of this specification or the accompanying drawings.
Number | Name | Date | Kind |
---|---|---|---|
382297 | Fry | May 1888 | A |
559697 | Tiugti et al. | May 1896 | A |
877946 | Overton | Feb 1908 | A |
975939 | William et al. | Nov 1910 | A |
1445642 | O'Neill | Feb 1923 | A |
1793068 | Dickinson | Feb 1931 | A |
2098340 | Henahan | Nov 1937 | A |
2436297 | Guarnaschelli | Feb 1948 | A |
2457052 | Le Clair | Dec 1948 | A |
2771644 | Martin | Nov 1956 | A |
2842382 | Franck | Jul 1958 | A |
2968497 | Treleman | Jan 1961 | A |
3127892 | Bellamy, Jr. et al. | Apr 1964 | A |
3262448 | Ring et al. | Jul 1966 | A |
3270743 | Gingras | Sep 1966 | A |
3301392 | Eddingfield | Jan 1967 | A |
3304047 | Martin | Feb 1967 | A |
3334860 | Bolton, Jr. | Aug 1967 | A |
3411665 | Blum | Nov 1968 | A |
3484121 | Quinton | Dec 1969 | A |
3485416 | Fohrman | Dec 1969 | A |
3538950 | Porteners | Nov 1970 | A |
3595241 | Sheridan | Jul 1971 | A |
3604582 | Boudin | Sep 1971 | A |
3707972 | Villari et al. | Jan 1973 | A |
3729031 | Baldwin | Apr 1973 | A |
3882858 | Klemm | May 1975 | A |
3977401 | Pike | Aug 1976 | A |
3977517 | Kadlecik et al. | Aug 1976 | A |
3987930 | Fuson | Oct 1976 | A |
3993066 | Virag | Nov 1976 | A |
4041934 | Genese | Aug 1977 | A |
4046889 | Ondetti et al. | Sep 1977 | A |
4052511 | Cushman et al. | Oct 1977 | A |
4053052 | Jasper | Oct 1977 | A |
4053651 | Ondetti et al. | Oct 1977 | A |
4066067 | Micheli | Jan 1978 | A |
4076285 | Martinez | Feb 1978 | A |
4078686 | Karesh et al. | Mar 1978 | A |
4079738 | Dunn et al. | Mar 1978 | A |
4095810 | Kulle | Jun 1978 | A |
4113751 | Arnold | Sep 1978 | A |
4121585 | Becker, Jr. | Oct 1978 | A |
4129571 | Ondetti et al. | Dec 1978 | A |
4133441 | Mittleman et al. | Jan 1979 | A |
4143853 | Abramson | Mar 1979 | A |
4150845 | Kopacz et al. | Apr 1979 | A |
4154840 | Ondetti et al. | May 1979 | A |
4154960 | Ondetti et al. | May 1979 | A |
4192443 | McLaren | Mar 1980 | A |
4194509 | Pickering et al. | Mar 1980 | A |
4195632 | Parker et al. | Apr 1980 | A |
4233982 | Bauer et al. | Nov 1980 | A |
4243035 | Barrett | Jan 1981 | A |
4245635 | Kontos | Jan 1981 | A |
4264664 | Kunz | Apr 1981 | A |
4280632 | Yuhara | Jul 1981 | A |
4294370 | Toeppen | Oct 1981 | A |
4317446 | Ambrosio et al. | Mar 1982 | A |
4324239 | Gordon et al. | Apr 1982 | A |
4325368 | Kaemmerer | Apr 1982 | A |
4331783 | Stoy | May 1982 | A |
4334551 | Pfister | Jun 1982 | A |
4335756 | Sharp et al. | Jun 1982 | A |
4337327 | Stoy | Jun 1982 | A |
4340049 | Munsch | Jul 1982 | A |
4340052 | Dennehey et al. | Jul 1982 | A |
4354490 | Rogers | Oct 1982 | A |
4369294 | Stoy | Jan 1983 | A |
4370451 | Stoy | Jan 1983 | A |
4379458 | Bauer et al. | Apr 1983 | A |
4379874 | Stoy | Apr 1983 | A |
4384589 | Morris | May 1983 | A |
4387879 | Tauschinski | Jun 1983 | A |
4390016 | Riess | Jun 1983 | A |
4397442 | Larkin | Aug 1983 | A |
4402691 | Rosenthal et al. | Sep 1983 | A |
4405312 | Gross et al. | Sep 1983 | A |
4417890 | Dennehey et al. | Nov 1983 | A |
4420589 | Stoy | Dec 1983 | A |
4427126 | Ostrowsky | Jan 1984 | A |
4430073 | Bemis et al. | Feb 1984 | A |
4432764 | Lopez | Feb 1984 | A |
4432766 | Bellotti et al. | Feb 1984 | A |
4436125 | Blenkush | Mar 1984 | A |
4439179 | Lueders et al. | Mar 1984 | A |
4439184 | Wheeler | Mar 1984 | A |
4440207 | Genatempo et al. | Apr 1984 | A |
4444310 | Odell | Apr 1984 | A |
4446967 | Halkyard | May 1984 | A |
4447419 | Quadro | May 1984 | A |
4457749 | Bellotti et al. | Jul 1984 | A |
4461368 | Plourde | Jul 1984 | A |
4461896 | Portlock | Jul 1984 | A |
4480940 | Woodruff | Nov 1984 | A |
4507111 | Gordon et al. | Mar 1985 | A |
4511359 | Vaillancourt | Apr 1985 | A |
4534764 | Mittleman et al. | Aug 1985 | A |
4538836 | Kruetten | Sep 1985 | A |
4559043 | Whitehouse | Dec 1985 | A |
4568675 | Bush et al. | Feb 1986 | A |
4585758 | Huang et al. | Apr 1986 | A |
4602042 | Chantler et al. | Jul 1986 | A |
4610469 | Wolff-Mooij | Sep 1986 | A |
4619640 | Potolsky et al. | Oct 1986 | A |
4623332 | Lindmayer et al. | Nov 1986 | A |
4624664 | Peluso et al. | Nov 1986 | A |
4626545 | Taub | Dec 1986 | A |
4629159 | Wellenstam | Dec 1986 | A |
4631188 | Stoy | Dec 1986 | A |
4642091 | Richmond | Feb 1987 | A |
4660803 | Johnston et al. | Apr 1987 | A |
4662878 | Lindmayer | May 1987 | A |
4666057 | Come et al. | May 1987 | A |
4666427 | Larsson et al. | May 1987 | A |
4671306 | Spector | Jun 1987 | A |
4671412 | Gatten | Jun 1987 | A |
4681886 | Haugwitz et al. | Jul 1987 | A |
4692458 | Ryan et al. | Sep 1987 | A |
4692459 | Ryan et al. | Sep 1987 | A |
4700744 | Rutter et al. | Oct 1987 | A |
4703762 | Rathbone et al. | Nov 1987 | A |
4705790 | Hubele et al. | Nov 1987 | A |
4723603 | Plummer | Feb 1988 | A |
4728075 | Paradis | Mar 1988 | A |
4728321 | Chen | Mar 1988 | A |
4738668 | Bellotti et al. | Apr 1988 | A |
4745950 | Mathieu | May 1988 | A |
4747502 | Luenser | May 1988 | A |
4748160 | Bennion et al. | May 1988 | A |
4752983 | Grieshaber | Jun 1988 | A |
4769013 | Lorenz et al. | Sep 1988 | A |
4774964 | Bonaldo | Oct 1988 | A |
4774965 | Rodriguez et al. | Oct 1988 | A |
4778447 | Velde et al. | Oct 1988 | A |
4781702 | Herrli | Nov 1988 | A |
4799926 | Haber | Jan 1989 | A |
4804015 | Albinsson | Feb 1989 | A |
4808158 | Kreuzer et al. | Feb 1989 | A |
4810241 | Rogers | Mar 1989 | A |
4811847 | Reif et al. | Mar 1989 | A |
4813933 | Turner | Mar 1989 | A |
4816024 | Sitar et al. | Mar 1989 | A |
4834271 | Litwin | May 1989 | A |
4862913 | Wildfang | Sep 1989 | A |
4874366 | Zdeb | Oct 1989 | A |
4883483 | Lindmayer | Nov 1989 | A |
4889255 | Schiemann et al. | Dec 1989 | A |
4894056 | Bommarito | Jan 1990 | A |
4898580 | Crowley | Feb 1990 | A |
4915687 | Sivert | Apr 1990 | A |
4917669 | Bonaldo | Apr 1990 | A |
4919658 | Badia | Apr 1990 | A |
4927019 | Haber et al. | May 1990 | A |
4935010 | Cox et al. | Jun 1990 | A |
4941873 | Fischer | Jul 1990 | A |
4950260 | Bonaldo | Aug 1990 | A |
4957637 | Cornell | Sep 1990 | A |
4963132 | Gibson | Oct 1990 | A |
D313277 | Haining | Dec 1990 | S |
D314050 | Sone | Jan 1991 | S |
4983161 | Dadson et al. | Jan 1991 | A |
4985017 | Theeuwes | Jan 1991 | A |
4989733 | Patry | Feb 1991 | A |
4991629 | Ernesto et al. | Feb 1991 | A |
4997371 | Fischer | Mar 1991 | A |
4999210 | Solomon | Mar 1991 | A |
5002964 | Loscalzo | Mar 1991 | A |
5006114 | Rogers et al. | Apr 1991 | A |
5015238 | Solomon et al. | May 1991 | A |
5019096 | Fox, Jr. et al. | May 1991 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5024657 | Needham et al. | Jun 1991 | A |
5025001 | Loscalzo et al. | Jun 1991 | A |
5026359 | Burroughs | Jun 1991 | A |
5031622 | LaHaye | Jul 1991 | A |
5033961 | Kandler et al. | Jul 1991 | A |
5047021 | Utterberg | Sep 1991 | A |
5049139 | Gilchrist | Sep 1991 | A |
5059186 | Yamamoto et al. | Oct 1991 | A |
5065783 | Ogle, II | Nov 1991 | A |
5070885 | Bonaldo | Dec 1991 | A |
5071411 | Hillstead | Dec 1991 | A |
5071413 | Utterberg | Dec 1991 | A |
5098385 | Walsh | Mar 1992 | A |
5108376 | Bonaldo | Apr 1992 | A |
5122123 | Vaillancourt | Jun 1992 | A |
5127626 | Hilal et al. | Jul 1992 | A |
5129824 | Keller | Jul 1992 | A |
5139483 | Ryan | Aug 1992 | A |
5143104 | Iba et al. | Sep 1992 | A |
5147333 | Raines | Sep 1992 | A |
5154703 | Bonaldo | Oct 1992 | A |
5154920 | Flesher et al. | Oct 1992 | A |
5184742 | DeCaprio et al. | Feb 1993 | A |
5190534 | Kendell | Mar 1993 | A |
5195957 | Tollini | Mar 1993 | A |
RE34223 | Bonaldo | Apr 1993 | E |
5199948 | McPhee | Apr 1993 | A |
5201725 | Kling | Apr 1993 | A |
5203775 | Frank et al. | Apr 1993 | A |
5205820 | Kriesel | Apr 1993 | A |
5205821 | Kruger et al. | Apr 1993 | A |
5207706 | Menaker | May 1993 | A |
5211634 | Vaillancourt | May 1993 | A |
5212204 | Keefer et al. | May 1993 | A |
5215537 | Lynn et al. | Jun 1993 | A |
5240675 | Wilk et al. | Aug 1993 | A |
5242421 | Chan | Sep 1993 | A |
5246011 | Caillouette | Sep 1993 | A |
5250550 | Keefer et al. | Oct 1993 | A |
5251873 | Atkinson et al. | Oct 1993 | A |
D342134 | Mongeon | Dec 1993 | S |
5269771 | Thomas et al. | Dec 1993 | A |
5278192 | Fung et al. | Jan 1994 | A |
5281206 | Lopez | Jan 1994 | A |
5284475 | Mackal | Feb 1994 | A |
5295657 | Atkinson | Mar 1994 | A |
5297310 | Cox et al. | Mar 1994 | A |
5301686 | Newman | Apr 1994 | A |
5304130 | Button | Apr 1994 | A |
5306243 | Bonaldo | Apr 1994 | A |
5312377 | Dalton | May 1994 | A |
5324270 | Kayan et al. | Jun 1994 | A |
5324647 | Rubens et al. | Jun 1994 | A |
5330426 | Kriesel et al. | Jul 1994 | A |
5330450 | Lopez | Jul 1994 | A |
5330899 | Devaughn et al. | Jul 1994 | A |
5337730 | Maguire | Aug 1994 | A |
5344414 | Lopez et al. | Sep 1994 | A |
5352410 | Hansen et al. | Oct 1994 | A |
5354267 | Niermann et al. | Oct 1994 | A |
5356396 | Wyatt et al. | Oct 1994 | A |
5360413 | Leason et al. | Nov 1994 | A |
5366505 | Farber | Nov 1994 | A |
5366997 | Keefer et al. | Nov 1994 | A |
5370614 | Amundson et al. | Dec 1994 | A |
5370636 | Von Witzleben | Dec 1994 | A |
5370640 | Kolff | Dec 1994 | A |
5375589 | Bhatta | Dec 1994 | A |
5380306 | Brinon | Jan 1995 | A |
5380758 | Stamler et al. | Jan 1995 | A |
5391150 | Richmond | Feb 1995 | A |
5402826 | Molnar et al. | Apr 1995 | A |
5405331 | Behnke et al. | Apr 1995 | A |
5405333 | Richmond | Apr 1995 | A |
5405919 | Keefer et al. | Apr 1995 | A |
5407807 | Markus | Apr 1995 | A |
5409012 | Sahatjian | Apr 1995 | A |
5411499 | Dudar et al. | May 1995 | A |
5417673 | Gordon | May 1995 | A |
5425465 | Healy | Jun 1995 | A |
5428070 | Cooke et al. | Jun 1995 | A |
5433330 | Yatsko et al. | Jul 1995 | A |
5433705 | Giebel et al. | Jul 1995 | A |
5439451 | Collinson et al. | Aug 1995 | A |
5441487 | Vedder | Aug 1995 | A |
5445623 | Richmond | Aug 1995 | A |
5456668 | Ogle, II | Oct 1995 | A |
5456675 | Wolbring et al. | Oct 1995 | A |
5464399 | Boettger | Nov 1995 | A |
5470307 | Lindall | Nov 1995 | A |
5470327 | Helgren et al. | Nov 1995 | A |
5471706 | Wallock et al. | Dec 1995 | A |
5474536 | Bonaldo | Dec 1995 | A |
5480393 | Bommarito | Jan 1996 | A |
5492147 | Challender et al. | Feb 1996 | A |
5496288 | Sweeney | Mar 1996 | A |
5501426 | Atkinson et al. | Mar 1996 | A |
5507733 | Larkin et al. | Apr 1996 | A |
5507744 | Tay et al. | Apr 1996 | A |
5514177 | Kurz et al. | May 1996 | A |
5518026 | Benjey | May 1996 | A |
5520665 | Fleetwood | May 1996 | A |
5520666 | Choudhury et al. | May 1996 | A |
5485827 | Zapol et al. | Jun 1996 | A |
5525357 | Keefer et al. | Jun 1996 | A |
5531695 | Swisher | Jul 1996 | A |
5533708 | Atkinson et al. | Jul 1996 | A |
5533983 | Haining | Jul 1996 | A |
5535785 | Werge et al. | Jul 1996 | A |
5536241 | Zapol | Jul 1996 | A |
5536258 | Folden | Jul 1996 | A |
5540661 | Tomisaka et al. | Jul 1996 | A |
5545614 | Stamler et al. | Aug 1996 | A |
5549566 | Elias et al. | Aug 1996 | A |
5549651 | Lynn | Aug 1996 | A |
5552115 | Malchesky | Sep 1996 | A |
5552118 | Mayer | Sep 1996 | A |
5554127 | Crouther et al. | Sep 1996 | A |
5554135 | Menyhay | Sep 1996 | A |
5555908 | Edwards et al. | Sep 1996 | A |
5569235 | Ross et al. | Oct 1996 | A |
5573516 | Tyner | Nov 1996 | A |
5575769 | Vaillancourt | Nov 1996 | A |
5578059 | Patzer | Nov 1996 | A |
5580530 | Kowatsch et al. | Dec 1996 | A |
5584819 | Kopfer | Dec 1996 | A |
5591137 | Stevens | Jan 1997 | A |
5591143 | Trombley, III et al. | Jan 1997 | A |
5597536 | Mayer | Jan 1997 | A |
5599352 | Dinh et al. | Feb 1997 | A |
5605696 | Eury et al. | Feb 1997 | A |
5607072 | Rigney et al. | Mar 1997 | A |
5613615 | Zeyfang et al. | Mar 1997 | A |
5616130 | Mayer | Apr 1997 | A |
5620088 | Martin et al. | Apr 1997 | A |
5620427 | Werschmidt et al. | Apr 1997 | A |
5624402 | Imbert | Apr 1997 | A |
5628733 | Zinreich et al. | May 1997 | A |
RE35539 | Bonaldo | Jun 1997 | E |
5645538 | Richmond | Jul 1997 | A |
5665077 | Resen et al. | Sep 1997 | A |
5674206 | Allton et al. | Oct 1997 | A |
5676346 | Leinsing | Oct 1997 | A |
5685866 | Lopez | Nov 1997 | A |
5685868 | Lundquist | Nov 1997 | A |
5688253 | Lundquist | Nov 1997 | A |
5694978 | Heilmann et al. | Dec 1997 | A |
5699821 | Paradis | Dec 1997 | A |
5700248 | Lopez | Dec 1997 | A |
5702017 | Goncalves | Dec 1997 | A |
5716339 | Tanaka et al. | Feb 1998 | A |
5722537 | Sigler | Mar 1998 | A |
5735826 | Richmond | Apr 1998 | A |
5738144 | Rogers | Apr 1998 | A |
5743892 | Loh et al. | Apr 1998 | A |
5749861 | Guala et al. | May 1998 | A |
5763409 | Bayol et al. | Jun 1998 | A |
5770645 | Stamler et al. | Jun 1998 | A |
5776116 | Lopez | Jul 1998 | A |
5782808 | Folden | Jul 1998 | A |
5782816 | Werschmidt et al. | Jul 1998 | A |
5785693 | Haining | Jul 1998 | A |
5792120 | Menyhay | Aug 1998 | A |
5797887 | Rosen et al. | Aug 1998 | A |
5806831 | Paradis | Sep 1998 | A |
5810792 | Fangrow, Jr. et al. | Sep 1998 | A |
5814024 | Thompson et al. | Sep 1998 | A |
5814666 | Green et al. | Sep 1998 | A |
5820601 | Mayer | Oct 1998 | A |
5820604 | Fox et al. | Oct 1998 | A |
5827244 | Boettger | Oct 1998 | A |
5839715 | Leinsing | Nov 1998 | A |
5848994 | Richmond | Dec 1998 | A |
5902631 | Wang et al. | May 1999 | A |
5941857 | Nguyen et al. | Aug 1999 | A |
5947954 | Bonaldo | Sep 1999 | A |
5951519 | Utterberg | Sep 1999 | A |
5954957 | Chin-Loy et al. | Sep 1999 | A |
5971972 | Rosenbaum | Oct 1999 | A |
D416086 | Parris et al. | Nov 1999 | S |
5989229 | Chiappetta | Nov 1999 | A |
5994444 | Trescony | Nov 1999 | A |
6029946 | Doyle | Feb 2000 | A |
6036171 | Weinheimer et al. | Mar 2000 | A |
6041805 | Gydesen et al. | Mar 2000 | A |
6045539 | Menyhay | Apr 2000 | A |
6045623 | Cannon | Apr 2000 | A |
6050978 | Orr et al. | Apr 2000 | A |
6059107 | Nosted et al. | May 2000 | A |
6063062 | Paradis | May 2000 | A |
6068011 | Paradis | May 2000 | A |
6068475 | Stoyka, Jr. et al. | May 2000 | A |
6068617 | Richmond | May 2000 | A |
6071413 | Dyke | Jun 2000 | A |
6079432 | Paradis | Jun 2000 | A |
6087479 | Stamler et al. | Jul 2000 | A |
6093743 | Lai et al. | Jul 2000 | A |
6095356 | Rits | Aug 2000 | A |
6099519 | Olsen et al. | Aug 2000 | A |
6105812 | Riordan | Aug 2000 | A |
6106502 | Richmond | Aug 2000 | A |
6113068 | Ryan | Sep 2000 | A |
6113572 | Gailey et al. | Sep 2000 | A |
6116468 | Nilson | Sep 2000 | A |
6117114 | Paradis | Sep 2000 | A |
6126640 | Tucker et al. | Oct 2000 | A |
6142446 | Leinsing | Nov 2000 | A |
6143318 | Gilchrist et al. | Nov 2000 | A |
6146363 | Giebel et al. | Nov 2000 | A |
6152913 | Feith et al. | Nov 2000 | A |
6158614 | Haines et al. | Dec 2000 | A |
6170522 | Tanida | Jan 2001 | B1 |
6171287 | Lynn et al. | Jan 2001 | B1 |
6174539 | Stamler et al. | Jan 2001 | B1 |
6179141 | Nakamura | Jan 2001 | B1 |
6183450 | Lois | Feb 2001 | B1 |
6202870 | Pearce | Mar 2001 | B1 |
6202901 | Gerber et al. | Mar 2001 | B1 |
6206134 | Stark et al. | Mar 2001 | B1 |
6206860 | Richmond | Mar 2001 | B1 |
6207855 | Toone et al. | Mar 2001 | B1 |
6217564 | Peters et al. | Apr 2001 | B1 |
6227391 | King | May 2001 | B1 |
6232406 | Stoy | May 2001 | B1 |
6232434 | Stamler et al. | May 2001 | B1 |
6237800 | Barrett et al. | May 2001 | B1 |
6242393 | Ishida et al. | Jun 2001 | B1 |
6245048 | Fangrow et al. | Jun 2001 | B1 |
6245056 | Walker et al. | Jun 2001 | B1 |
6248380 | Kocher et al. | Jun 2001 | B1 |
6250315 | Ernster | Jun 2001 | B1 |
6255277 | Stamler et al. | Jul 2001 | B1 |
6267754 | Peters | Jul 2001 | B1 |
6299132 | Weinheimer et al. | Oct 2001 | B1 |
6315113 | Britton et al. | Nov 2001 | B1 |
6315761 | Shcherbina et al. | Nov 2001 | B1 |
6359167 | Toone et al. | Mar 2002 | B2 |
6359182 | Stamler et al. | Mar 2002 | B1 |
6375231 | Picha et al. | Apr 2002 | B1 |
6379660 | Saavedra et al. | Apr 2002 | B1 |
6379691 | Tedeschi et al. | Apr 2002 | B1 |
6394983 | Mayoral et al. | May 2002 | B1 |
6402207 | Segal et al. | Jun 2002 | B1 |
6403759 | Stamler et al. | Jun 2002 | B2 |
6409716 | Sahatjian et al. | Jun 2002 | B1 |
6428520 | Lopez | Aug 2002 | B1 |
6431219 | Redler et al. | Aug 2002 | B1 |
6444318 | Guire et al. | Sep 2002 | B1 |
6468259 | Djokic et al. | Oct 2002 | B1 |
6471978 | Stamler et al. | Oct 2002 | B1 |
6488951 | Toone et al. | Dec 2002 | B2 |
6491965 | Berry et al. | Dec 2002 | B1 |
6499719 | Clancy et al. | Dec 2002 | B1 |
6508792 | Szames et al. | Jan 2003 | B2 |
6508807 | Peters | Jan 2003 | B1 |
6538116 | Stamler et al. | Mar 2003 | B2 |
6541802 | Doyle | Apr 2003 | B2 |
6543745 | Enerson | Apr 2003 | B1 |
6550493 | Williamson et al. | Apr 2003 | B2 |
6555504 | Ayai et al. | Apr 2003 | B1 |
6562781 | Berry et al. | May 2003 | B1 |
6581906 | Pott et al. | Jun 2003 | B2 |
6583311 | Toone et al. | Jun 2003 | B2 |
6585691 | Vitello | Jul 2003 | B1 |
6595964 | Finley et al. | Jul 2003 | B2 |
6595981 | Huet | Jul 2003 | B2 |
6605294 | Sawhney | Aug 2003 | B2 |
6605751 | Gibbins et al. | Aug 2003 | B1 |
6609696 | Enerson | Aug 2003 | B2 |
6632199 | Tucker et al. | Oct 2003 | B1 |
6634498 | Kayerod et al. | Oct 2003 | B2 |
6656217 | Herzog, Jr. et al. | Dec 2003 | B1 |
6666852 | Niedospial, Jr. | Dec 2003 | B2 |
6673891 | Stamler et al. | Jan 2004 | B2 |
6679395 | Pfefferkorn et al. | Jan 2004 | B1 |
6679870 | Finch et al. | Jan 2004 | B1 |
6681803 | Taneya et al. | Jan 2004 | B2 |
6685694 | Finch et al. | Feb 2004 | B2 |
6692468 | Waldenburg | Feb 2004 | B1 |
6695817 | Fangrow | Feb 2004 | B1 |
6716396 | Anderson | Apr 2004 | B1 |
6722705 | Korkor | Apr 2004 | B2 |
6725492 | Moore et al. | Apr 2004 | B2 |
6745998 | Doyle | Jun 2004 | B2 |
6786884 | DeCant, Jr. et al. | Sep 2004 | B1 |
6808510 | DiFiore | Oct 2004 | B1 |
6827766 | Carnes et al. | Dec 2004 | B2 |
6840501 | Doyle | Jan 2005 | B2 |
6871087 | Hughes et al. | Mar 2005 | B1 |
6875205 | Leinsing | Apr 2005 | B2 |
6875840 | Stamler et al. | Apr 2005 | B2 |
6887994 | Stamler et al. | May 2005 | B2 |
6899315 | Mailville et al. | May 2005 | B2 |
6911025 | Miyahar | Jun 2005 | B2 |
6916051 | Fisher | Jul 2005 | B2 |
6929005 | Sullivan et al. | Aug 2005 | B2 |
6943035 | Davies et al. | Sep 2005 | B1 |
6955669 | Curutcharry | Oct 2005 | B2 |
6964406 | Doyle | Nov 2005 | B2 |
7004934 | Vaillancourt | Feb 2006 | B2 |
7015347 | Toone et al. | Mar 2006 | B2 |
7030238 | Stamler et al. | Apr 2006 | B2 |
7037302 | Vaillancourt | May 2006 | B2 |
7040598 | Raybuck | May 2006 | B2 |
7044441 | Doyle | May 2006 | B2 |
7045585 | Berry et al. | May 2006 | B2 |
7049308 | Stamler et al. | May 2006 | B2 |
7052711 | West et al. | May 2006 | B2 |
7056308 | Utterberg | Jun 2006 | B2 |
7067659 | Stamler et al. | Jun 2006 | B2 |
7081109 | Tighe et al. | Jul 2006 | B2 |
7083605 | Miyahara | Aug 2006 | B2 |
7087709 | Stamler et al. | Aug 2006 | B2 |
7097850 | Chappa et al. | Aug 2006 | B2 |
7100891 | Doyle | Sep 2006 | B2 |
7125396 | Leinsing et al. | Oct 2006 | B2 |
7140592 | Phillips | Nov 2006 | B2 |
7147625 | Sarangapani et al. | Dec 2006 | B2 |
7160272 | Eyal et al. | Jan 2007 | B1 |
7182313 | Doyle | Feb 2007 | B2 |
7195615 | Tan | Mar 2007 | B2 |
7198611 | Connell et al. | Apr 2007 | B2 |
7244249 | Leinsing et al. | Jul 2007 | B2 |
7259250 | Stamler et al. | Aug 2007 | B2 |
7279176 | West et al. | Oct 2007 | B1 |
7282186 | Lake, Jr. et al. | Oct 2007 | B2 |
7306197 | Parrino et al. | Dec 2007 | B2 |
7306198 | Doyle | Dec 2007 | B2 |
7306566 | Raybuck | Dec 2007 | B2 |
7309326 | Fangrow, Jr. | Dec 2007 | B2 |
7316669 | Ranalletta | Jan 2008 | B2 |
7347458 | Rome et al. | Mar 2008 | B2 |
7347853 | DiFiore et al. | Mar 2008 | B2 |
7350764 | Raybuck | Apr 2008 | B2 |
7361164 | Simpson et al. | Apr 2008 | B2 |
7417109 | Stamler et al. | Aug 2008 | B2 |
7431712 | Kim | Oct 2008 | B2 |
7442402 | Chudzik et al. | Oct 2008 | B2 |
7452349 | Miyahar | Nov 2008 | B2 |
7485107 | DiFiore et al. | Feb 2009 | B2 |
7491192 | DiFiore | Feb 2009 | B2 |
7497484 | Ziman | Mar 2009 | B2 |
7516846 | Hansen | Apr 2009 | B2 |
7588563 | Guala | Sep 2009 | B2 |
7611505 | Ranalletta et al. | Nov 2009 | B2 |
7614426 | Kitani et al. | Nov 2009 | B2 |
7615034 | DiFiore | Nov 2009 | B2 |
7625907 | Stamler et al. | Dec 2009 | B2 |
7635344 | Tennican et al. | Dec 2009 | B2 |
D607325 | Rogers et al. | Jan 2010 | S |
7645274 | Whitley | Jan 2010 | B2 |
7651481 | Raybuck | Jan 2010 | B2 |
7666170 | Guala | Feb 2010 | B2 |
7708714 | Connell et al. | May 2010 | B2 |
7731678 | Tennican et al. | Jun 2010 | B2 |
7731679 | Tennican et al. | Jun 2010 | B2 |
7749189 | Tennican et al. | Jul 2010 | B2 |
7753891 | Tennican et al. | Jul 2010 | B2 |
7758530 | DiFiore et al. | Jul 2010 | B2 |
7758566 | Simpson et al. | Jul 2010 | B2 |
7762524 | Cawthon et al. | Jul 2010 | B2 |
7763006 | Tennican | Jul 2010 | B2 |
7766182 | Trent et al. | Aug 2010 | B2 |
7766897 | Ramsey et al. | Aug 2010 | B2 |
7776011 | Tennican et al. | Aug 2010 | B2 |
7780794 | Rogers et al. | Aug 2010 | B2 |
7785616 | Stamler et al. | Aug 2010 | B2 |
7794675 | Lynn | Sep 2010 | B2 |
7799010 | Tennican | Sep 2010 | B2 |
7803139 | Fangrow, Jr. | Sep 2010 | B2 |
7803140 | Fangrow, Jr. | Sep 2010 | B2 |
7815614 | Fangrow, Jr. | Oct 2010 | B2 |
7857793 | Raulerson et al. | Dec 2010 | B2 |
7922701 | Buchman | Apr 2011 | B2 |
7922711 | Ranalletta et al. | Apr 2011 | B2 |
7928079 | Hrabie et al. | Apr 2011 | B2 |
7938795 | DiFiore et al. | May 2011 | B2 |
7956062 | Stamler et al. | Jun 2011 | B2 |
7959026 | Bertani | Jun 2011 | B2 |
7963565 | Suter | Jun 2011 | B2 |
7972137 | Rosen | Jul 2011 | B2 |
7972322 | Tennican | Jul 2011 | B2 |
7981090 | Plishka et al. | Jul 2011 | B2 |
7985302 | Rogers et al. | Jul 2011 | B2 |
7993309 | Schweikert | Aug 2011 | B2 |
7998134 | Fangrow et al. | Aug 2011 | B2 |
8034454 | Terry | Oct 2011 | B2 |
8065773 | Vaillancourt et al. | Nov 2011 | B2 |
8066670 | Cluff et al. | Nov 2011 | B2 |
8069523 | Vaillancourt et al. | Dec 2011 | B2 |
8113837 | Zegarelli | Feb 2012 | B2 |
8146757 | Abreu et al. | Apr 2012 | B2 |
8162899 | Tennican | Apr 2012 | B2 |
8167847 | Anderson et al. | May 2012 | B2 |
8172825 | Solomon et al. | May 2012 | B2 |
8177761 | Howlett et al. | May 2012 | B2 |
8177772 | Christensen et al. | May 2012 | B2 |
8197749 | Howlett et al. | Jun 2012 | B2 |
8206514 | Rogers et al. | Jun 2012 | B2 |
8231587 | Solomon et al. | Jul 2012 | B2 |
8231602 | Anderson et al. | Jul 2012 | B2 |
8252247 | Ferlic | Aug 2012 | B2 |
8262628 | Fangrow, Jr. | Sep 2012 | B2 |
8262643 | Tennican | Sep 2012 | B2 |
8273303 | Ferlic et al. | Sep 2012 | B2 |
8281824 | Molema et al. | Oct 2012 | B2 |
8328767 | Solomon et al. | Dec 2012 | B2 |
8336152 | Kerr et al. | Dec 2012 | B2 |
8343112 | Solomon et al. | Jan 2013 | B2 |
8361408 | Lynn | Jan 2013 | B2 |
8372045 | Needle et al. | Feb 2013 | B2 |
8377040 | Burkholz et al. | Feb 2013 | B2 |
8414547 | DiFiore et al. | Apr 2013 | B2 |
8419713 | Solomon et al. | Apr 2013 | B1 |
8454579 | Fangrow, Jr. | Jun 2013 | B2 |
8480968 | Lynn | Jul 2013 | B2 |
8491546 | Hoang et al. | Jul 2013 | B2 |
8500717 | Becker | Aug 2013 | B2 |
8506527 | Carlyon | Aug 2013 | B2 |
8506538 | Chelak | Aug 2013 | B2 |
8523798 | DiFiore | Sep 2013 | B2 |
8523830 | Solomon et al. | Sep 2013 | B2 |
8523831 | Solomon et al. | Sep 2013 | B2 |
8533887 | Hirst | Sep 2013 | B2 |
8545479 | Kitani et al. | Oct 2013 | B2 |
8568371 | Siopes et al. | Oct 2013 | B2 |
8622995 | Ziebol et al. | Jan 2014 | B2 |
8622996 | Ziebol et al. | Jan 2014 | B2 |
8641681 | Solomon et al. | Feb 2014 | B2 |
8641684 | Utterberg et al. | Feb 2014 | B2 |
8647308 | Solomon et al. | Feb 2014 | B2 |
8647326 | Solomon et al. | Feb 2014 | B2 |
8651271 | Shen | Feb 2014 | B1 |
8671496 | Kerr et al. | Mar 2014 | B2 |
8740864 | Hoang et al. | Jun 2014 | B2 |
8758307 | Grimm et al. | Jun 2014 | B2 |
8777504 | Shaw et al. | Jul 2014 | B2 |
8791073 | West et al. | Jul 2014 | B2 |
8845593 | Anderson et al. | Sep 2014 | B2 |
8877231 | Rosen | Nov 2014 | B2 |
8910919 | Bonnal et al. | Dec 2014 | B2 |
8920404 | DiFiore et al. | Dec 2014 | B2 |
8968268 | Anderson et al. | Mar 2015 | B2 |
8981139 | Schoenfisch et al. | Mar 2015 | B2 |
8999073 | Rogers et al. | Apr 2015 | B2 |
9022984 | Ziebol et al. | May 2015 | B2 |
9072296 | Mills et al. | Jul 2015 | B2 |
9072868 | Ziebol et al. | Jul 2015 | B2 |
9078992 | Ziebol et al. | Jul 2015 | B2 |
9089680 | Ueda et al. | Jul 2015 | B2 |
9095500 | Brandenburger et al. | Aug 2015 | B2 |
9095667 | Von Schuckmann | Aug 2015 | B2 |
9101685 | Li et al. | Aug 2015 | B2 |
9101750 | Solomon et al. | Aug 2015 | B2 |
9114915 | Solomon et al. | Aug 2015 | B2 |
9125600 | Steube et al. | Sep 2015 | B2 |
9149624 | Lewis | Oct 2015 | B2 |
9180252 | Gelblum et al. | Nov 2015 | B2 |
9192449 | Kerr et al. | Nov 2015 | B2 |
9205248 | Wu et al. | Dec 2015 | B2 |
9216440 | Ma et al. | Dec 2015 | B2 |
9233208 | Tekeste | Jan 2016 | B2 |
9242084 | Solomon et al. | Jan 2016 | B2 |
9248093 | Kelley, III et al. | Feb 2016 | B2 |
9248229 | Devouassoux et al. | Feb 2016 | B2 |
9259284 | Rogers et al. | Feb 2016 | B2 |
9259535 | Anderson et al. | Feb 2016 | B2 |
9283367 | Hoang et al. | Mar 2016 | B2 |
9283368 | Hoang et al. | Mar 2016 | B2 |
9283369 | Ma et al. | Mar 2016 | B2 |
9289588 | Chen | Mar 2016 | B2 |
9296525 | Murphy et al. | Mar 2016 | B2 |
9302049 | Tekeste | Apr 2016 | B2 |
9320858 | Grimm et al. | Apr 2016 | B2 |
9320859 | Grimm et al. | Apr 2016 | B2 |
9320860 | Grimm et al. | Apr 2016 | B2 |
9352080 | Goodall et al. | May 2016 | B2 |
9352140 | Kerr et al. | May 2016 | B2 |
9352141 | Wong | May 2016 | B2 |
9352142 | Ziebol et al. | May 2016 | B2 |
9381339 | Wu et al. | Jul 2016 | B2 |
9399125 | Burkholz | Jul 2016 | B2 |
9408971 | Carlyon | Aug 2016 | B2 |
9527660 | Tennican | Dec 2016 | B2 |
9592375 | Tennican | Mar 2017 | B2 |
9700676 | Anderson et al. | Jul 2017 | B2 |
9700677 | Anderson et al. | Jul 2017 | B2 |
9700710 | Anderson et al. | Jul 2017 | B2 |
9707348 | Anderson et al. | Jul 2017 | B2 |
9707349 | Anderson et al. | Jul 2017 | B2 |
9707350 | Anderson et al. | Jul 2017 | B2 |
9809355 | Solomon et al. | Nov 2017 | B2 |
9849276 | Ziebol et al. | Dec 2017 | B2 |
9867975 | Gardner et al. | Jan 2018 | B2 |
9907617 | Rogers | Mar 2018 | B2 |
9933094 | Fangrow | Apr 2018 | B2 |
9999471 | Rogers et al. | Jun 2018 | B2 |
10016587 | Gardner et al. | Jul 2018 | B2 |
10046156 | Gardner et al. | Aug 2018 | B2 |
10159829 | Ziebol et al. | Dec 2018 | B2 |
10166381 | Gardner et al. | Jan 2019 | B2 |
10195000 | Rogers et al. | Feb 2019 | B2 |
10201692 | Chang | Feb 2019 | B2 |
10328207 | Anderson et al. | Jun 2019 | B2 |
10525250 | Ziebol et al. | Jan 2020 | B1 |
10695550 | Gardner et al. | Jun 2020 | B2 |
10744316 | Fangrow | Aug 2020 | B2 |
10806919 | Gardner et al. | Oct 2020 | B2 |
10821278 | Gardner et al. | Nov 2020 | B2 |
11160932 | Anderson et al. | Nov 2021 | B2 |
11229746 | Anderson et al. | Jan 2022 | B2 |
20020077693 | Barclay et al. | Jun 2002 | A1 |
20020082682 | Barclay et al. | Jun 2002 | A1 |
20020098278 | Bates et al. | Jun 2002 | A1 |
20030039697 | Zhao et al. | Feb 2003 | A1 |
20030062376 | Sears et al. | Apr 2003 | A1 |
20030072783 | Stamler et al. | Apr 2003 | A1 |
20030153865 | Connell et al. | Aug 2003 | A1 |
20030199835 | Leinsing et al. | Oct 2003 | A1 |
20030208165 | Christensen et al. | Nov 2003 | A1 |
20040034042 | Tsuji et al. | Feb 2004 | A1 |
20040034329 | Mankus et al. | Feb 2004 | A1 |
20040037836 | Stamler et al. | Feb 2004 | A1 |
20040048542 | Thomaschefsky et al. | Mar 2004 | A1 |
20040052689 | Yao | Mar 2004 | A1 |
20040052831 | Modak et al. | Mar 2004 | A1 |
20040156908 | Polaschegg et al. | Aug 2004 | A1 |
20040210201 | Farnan | Oct 2004 | A1 |
20040215148 | Hwang et al. | Oct 2004 | A1 |
20040247640 | Zhao et al. | Dec 2004 | A1 |
20040249337 | DiFiore | Dec 2004 | A1 |
20040249338 | DeCant, Jr. et al. | Dec 2004 | A1 |
20050013836 | Raad | Jan 2005 | A1 |
20050015075 | Wright et al. | Jan 2005 | A1 |
20050065479 | Schiller et al. | Mar 2005 | A1 |
20050098527 | Yates et al. | May 2005 | A1 |
20050124942 | Richmond | Jun 2005 | A1 |
20050124970 | Kunin et al. | Jun 2005 | A1 |
20050147524 | Bousquet | Jul 2005 | A1 |
20050147525 | Bousquet | Jul 2005 | A1 |
20050148930 | Hseih et al. | Jul 2005 | A1 |
20050152891 | Toone et al. | Jul 2005 | A1 |
20050171493 | Nicholls | Aug 2005 | A1 |
20050214185 | Castaneda | Sep 2005 | A1 |
20050220882 | Pritchard et al. | Oct 2005 | A1 |
20050228362 | Vaillancourt | Oct 2005 | A1 |
20050228482 | Herzog et al. | Oct 2005 | A1 |
20050256461 | DiFiore et al. | Nov 2005 | A1 |
20050265958 | West et al. | Dec 2005 | A1 |
20050267421 | Wing | Dec 2005 | A1 |
20050271711 | Lynch | Dec 2005 | A1 |
20050288551 | Callister et al. | Dec 2005 | A1 |
20060004316 | DiFiore et al. | Jan 2006 | A1 |
20060024372 | Utterberg et al. | Feb 2006 | A1 |
20060058734 | Phillips | Mar 2006 | A1 |
20060096348 | DiFiore | May 2006 | A1 |
20060118122 | Martens et al. | Jun 2006 | A1 |
20060129109 | Shaw et al. | Jun 2006 | A1 |
20060142730 | Proulx et al. | Jun 2006 | A1 |
20060149191 | DiFiore | Jul 2006 | A1 |
20060161115 | Fangrow | Jul 2006 | A1 |
20060195117 | Rucker et al. | Aug 2006 | A1 |
20060202146 | Doyle | Sep 2006 | A1 |
20060206178 | Kim | Sep 2006 | A1 |
20060253084 | Nordgren | Nov 2006 | A1 |
20060261076 | Anderson | Nov 2006 | A1 |
20070003603 | Karandikar et al. | Jan 2007 | A1 |
20070088292 | Fangrow | Apr 2007 | A1 |
20070088293 | Fangrow | Apr 2007 | A1 |
20070088294 | Fangrow | Apr 2007 | A1 |
20070106205 | Connell et al. | May 2007 | A1 |
20070167910 | Tennican et al. | Jul 2007 | A1 |
20070179453 | Lim et al. | Aug 2007 | A1 |
20070187353 | Fox et al. | Aug 2007 | A1 |
20070212381 | DiFiore et al. | Sep 2007 | A1 |
20070231315 | Lichte et al. | Oct 2007 | A1 |
20070248676 | Stamler et al. | Oct 2007 | A1 |
20070249996 | Tennican et al. | Oct 2007 | A1 |
20070265578 | Tennican et al. | Nov 2007 | A1 |
20070287989 | Crawford et al. | Dec 2007 | A1 |
20080027399 | Harding et al. | Jan 2008 | A1 |
20080027401 | Ou-Yang | Jan 2008 | A1 |
20080033371 | Updegraff et al. | Feb 2008 | A1 |
20080039803 | Lynn | Feb 2008 | A1 |
20080058733 | Vogt et al. | Mar 2008 | A1 |
20080093245 | Periasamy et al. | Apr 2008 | A1 |
20080095680 | Steffens et al. | Apr 2008 | A1 |
20080097315 | Miner et al. | Apr 2008 | A1 |
20080097407 | Plishka | Apr 2008 | A1 |
20080103485 | Kruger | May 2008 | A1 |
20080287920 | Fangrow et al. | May 2008 | A1 |
20080014005 | Shirley | Jun 2008 | A1 |
20080128646 | Clawson | Jun 2008 | A1 |
20080147047 | Davis et al. | Jun 2008 | A1 |
20080161763 | Harding et al. | Jul 2008 | A1 |
20080172007 | Bousquet | Jul 2008 | A1 |
20080177250 | Howlett et al. | Jul 2008 | A1 |
20080187460 | Utterberg et al. | Aug 2008 | A1 |
20080188791 | DiFiore et al. | Aug 2008 | A1 |
20080190485 | Guala | Aug 2008 | A1 |
20080262465 | Zinger et al. | Oct 2008 | A1 |
20080318333 | Nielsen et al. | Dec 2008 | A1 |
20080319423 | Tanghoj et al. | Dec 2008 | A1 |
20090008393 | Howlett et al. | Jan 2009 | A1 |
20090012426 | Tennican | Jan 2009 | A1 |
20090024096 | Hai et al. | Jan 2009 | A1 |
20090028750 | Ryan | Jan 2009 | A1 |
20090062766 | Howlett et al. | Mar 2009 | A1 |
20090093757 | Tennican | Apr 2009 | A1 |
20090126867 | Decant, Jr. et al. | May 2009 | A1 |
20090137969 | Colantonio et al. | May 2009 | A1 |
20090149820 | DiFiore | Jun 2009 | A1 |
20090163876 | Chebator et al. | Jun 2009 | A1 |
20090205151 | Fisher et al. | Aug 2009 | A1 |
20090205656 | Nishibayashi et al. | Aug 2009 | A1 |
20090247485 | Ahmed et al. | Oct 2009 | A1 |
20090259194 | Pinedjian et al. | Oct 2009 | A1 |
20090270832 | Vancaillie et al. | Oct 2009 | A1 |
20090293882 | Terry | Dec 2009 | A1 |
20100004510 | Kuroshima | Jan 2010 | A1 |
20100049170 | Solomon et al. | Feb 2010 | A1 |
20100050351 | Colantonio et al. | Mar 2010 | A1 |
20100064456 | Ferlic | Mar 2010 | A1 |
20100074932 | Talsma | Mar 2010 | A1 |
20100137472 | Ou-Yang | Jun 2010 | A1 |
20100143427 | King et al. | Jun 2010 | A1 |
20100152670 | Low | Jun 2010 | A1 |
20100160894 | Julian et al. | Jun 2010 | A1 |
20100172794 | Ferlic et al. | Jul 2010 | A1 |
20100242993 | Hoang et al. | Sep 2010 | A1 |
20100253070 | Cheon et al. | Oct 2010 | A1 |
20100280805 | DiFiore | Nov 2010 | A1 |
20100292673 | Korogi et al. | Nov 2010 | A1 |
20100292674 | Jepson et al. | Nov 2010 | A1 |
20100306938 | Rogers et al. | Dec 2010 | A1 |
20100318040 | Kelley, III et al. | Dec 2010 | A1 |
20110030726 | Vaillancourt et al. | Feb 2011 | A1 |
20110044850 | Solomon et al. | Feb 2011 | A1 |
20110046564 | Zhong | Feb 2011 | A1 |
20110046603 | Felsovalyi et al. | Feb 2011 | A1 |
20110062703 | Lopez | Mar 2011 | A1 |
20110064512 | Shaw et al. | Mar 2011 | A1 |
20110071475 | Horvath et al. | Mar 2011 | A1 |
20110082431 | Burgess et al. | Apr 2011 | A1 |
20110184338 | McKay | Jul 2011 | A1 |
20110184382 | Cady | Jul 2011 | A1 |
20110208128 | Wu et al. | Aug 2011 | A1 |
20110217212 | Solomon et al. | Sep 2011 | A1 |
20110276031 | Hoang et al. | Nov 2011 | A1 |
20110282302 | Lopez et al. | Nov 2011 | A1 |
20110311602 | Mills et al. | Dec 2011 | A1 |
20110314619 | Schweikert | Dec 2011 | A1 |
20120022469 | Albert et al. | Jan 2012 | A1 |
20120031904 | Kuhn et al. | Feb 2012 | A1 |
20120039764 | Solomon et al. | Feb 2012 | A1 |
20120083730 | Rush et al. | Apr 2012 | A1 |
20120083750 | Sansoucy | Apr 2012 | A1 |
20120157965 | Wotton et al. | Jun 2012 | A1 |
20120191029 | Hopf et al. | Jul 2012 | A1 |
20120195807 | Ferlic | Aug 2012 | A1 |
20120216359 | Rogers et al. | Aug 2012 | A1 |
20120216360 | Rogers et al. | Aug 2012 | A1 |
20120220955 | Maseda et al. | Aug 2012 | A1 |
20120283696 | Cronenberg et al. | Nov 2012 | A1 |
20120302968 | Tennican | Nov 2012 | A1 |
20120302970 | Tennican | Nov 2012 | A1 |
20120302997 | Gardner et al. | Nov 2012 | A1 |
20120315201 | Ferlic et al. | Dec 2012 | A1 |
20130030414 | Gardner et al. | Jan 2013 | A1 |
20130035667 | Anderson et al. | Feb 2013 | A1 |
20130039953 | Dudnyk et al. | Feb 2013 | A1 |
20130053751 | Holtham | Feb 2013 | A1 |
20130072908 | Solomon et al. | Mar 2013 | A1 |
20130085313 | Fowler et al. | Apr 2013 | A1 |
20130085474 | Charles et al. | Apr 2013 | A1 |
20130098398 | Kerr et al. | Apr 2013 | A1 |
20130098938 | Efthimiadis | Apr 2013 | A1 |
20130102950 | DiFiore | Apr 2013 | A1 |
20130123754 | Solomon et al. | May 2013 | A1 |
20130134161 | Fogel et al. | May 2013 | A1 |
20130138085 | Tennican | May 2013 | A1 |
20130144258 | Ziebol et al. | Jun 2013 | A1 |
20130150795 | Snow | Jun 2013 | A1 |
20130164189 | Hadden | Jun 2013 | A1 |
20130171030 | Ferlic et al. | Jul 2013 | A1 |
20130183635 | Wilhoit | Jul 2013 | A1 |
20130197485 | Gardner et al. | Aug 2013 | A1 |
20140042116 | Shen et al. | Feb 2014 | A1 |
20140048079 | Gardner et al. | Feb 2014 | A1 |
20140052074 | Tekeste | Feb 2014 | A1 |
20140101876 | Rogers et al. | Apr 2014 | A1 |
20140155868 | Nelson et al. | Jun 2014 | A1 |
20140227144 | Liu et al. | Aug 2014 | A1 |
20140228775 | Burkholz et al. | Aug 2014 | A1 |
20140228809 | Wong | Aug 2014 | A1 |
20140243797 | Jensen et al. | Aug 2014 | A1 |
20140249476 | Grimm et al. | Sep 2014 | A1 |
20140249477 | Grimm et al. | Sep 2014 | A1 |
20140249486 | Grimm et al. | Sep 2014 | A1 |
20140336610 | Michel | Nov 2014 | A1 |
20140339812 | Carney et al. | Nov 2014 | A1 |
20140339813 | Cederschiöld et al. | Nov 2014 | A1 |
20150141934 | Gardner et al. | May 2015 | A1 |
20150148287 | Woo et al. | May 2015 | A1 |
20150165127 | Haefele et al. | Jun 2015 | A1 |
20150217106 | Banik et al. | Aug 2015 | A1 |
20150231380 | Hoang et al. | Aug 2015 | A1 |
20150237854 | Mills et al. | Aug 2015 | A1 |
20150238703 | Glocker | Aug 2015 | A1 |
20150258324 | Chida et al. | Sep 2015 | A1 |
20150273199 | Adams et al. | Oct 2015 | A1 |
20150297455 | Sanders et al. | Oct 2015 | A1 |
20150297881 | Sanders et al. | Oct 2015 | A1 |
20150306367 | DiFiore | Oct 2015 | A1 |
20150306369 | Burkholz et al. | Oct 2015 | A1 |
20150314119 | Anderson et al. | Nov 2015 | A1 |
20150320926 | Fitzpatrick et al. | Nov 2015 | A1 |
20150320992 | Bonnet et al. | Nov 2015 | A1 |
20150343174 | Ziebol et al. | Dec 2015 | A1 |
20150374968 | Solomon et al. | Dec 2015 | A1 |
20160001056 | Nelson et al. | Jan 2016 | A1 |
20160001058 | Ziebol et al. | Jan 2016 | A1 |
20160015863 | Gupta et al. | Jan 2016 | A1 |
20160015931 | Ryan et al. | Jan 2016 | A1 |
20160015959 | Solomon et al. | Jan 2016 | A1 |
20160045629 | Gardner et al. | Feb 2016 | A1 |
20160067365 | Ma et al. | Mar 2016 | A1 |
20160067471 | Ingram et al. | Mar 2016 | A1 |
20160088995 | Ueda et al. | Mar 2016 | A1 |
20160089530 | Sathe | Mar 2016 | A1 |
20160101223 | Kelley, III et al. | Apr 2016 | A1 |
20160101276 | Tekeste | Apr 2016 | A1 |
20160106969 | Neftel | Apr 2016 | A1 |
20160121097 | Steele | May 2016 | A1 |
20160144118 | Solomon et al. | May 2016 | A1 |
20160158520 | Ma et al. | Jun 2016 | A1 |
20160158521 | Hoang et al. | Jun 2016 | A1 |
20160158522 | Hoang et al. | Jun 2016 | A1 |
20160184527 | Tekeste | Jun 2016 | A1 |
20160213912 | Daneluzzi | Jul 2016 | A1 |
20160250420 | Maritan et al. | Sep 2016 | A1 |
20160354596 | DiFiore | Dec 2016 | A1 |
20170020911 | Berry et al. | Jan 2017 | A1 |
20170042636 | Young | Feb 2017 | A1 |
20170143447 | Rogers et al. | May 2017 | A1 |
20170182241 | DiFiore | Jun 2017 | A1 |
20170203092 | Ryan et al. | Jul 2017 | A1 |
20170239443 | Abitabilo et al. | Aug 2017 | A1 |
20170361023 | Anderson et al. | Dec 2017 | A1 |
20180028403 | Fangrow | Feb 2018 | A1 |
20180200500 | Ziebol et al. | Jul 2018 | A1 |
20180214684 | Avula et al. | Aug 2018 | A1 |
20180369562 | Gardner | Dec 2018 | A1 |
20190038888 | Gardner | Feb 2019 | A1 |
20190111245 | Gardner et al. | Apr 2019 | A1 |
20190201681 | Ziebol et al. | Jul 2019 | A1 |
20190282795 | Fangrow | Sep 2019 | A1 |
20200085690 | Fangrow | Mar 2020 | A1 |
20200139037 | Ziebol et al. | May 2020 | A1 |
20200139101 | Ziebol et al. | May 2020 | A1 |
20200139102 | Ziebol et al. | May 2020 | A1 |
20200139103 | Ziebol et al. | May 2020 | A1 |
20200139104 | Ziebol et al. | May 2020 | A1 |
20200155794 | Ziebol | May 2020 | A1 |
20200324102 | Fangrow | Oct 2020 | A1 |
20200330741 | Fangrow | Oct 2020 | A1 |
20200406020 | Fangrow | Dec 2020 | A1 |
20210093791 | Anderson | Apr 2021 | A1 |
20210162194 | Gardner | Jun 2021 | A1 |
20210205596 | Ziebol et al. | Jul 2021 | A1 |
20210308442 | Gardner | Oct 2021 | A1 |
Number | Date | Country |
---|---|---|
2 148 847 | Dec 1995 | CA |
2825217 | Mar 2007 | CA |
2 841 832 | Jun 2019 | CA |
2402327 | Oct 2000 | CN |
2815392 | Sep 2006 | CN |
201150420 | Nov 2008 | CN |
201519335 | Jul 2010 | CN |
106902402 | Jun 2017 | CN |
3515665 | May 1986 | DE |
89 06 628 | Sep 1989 | DE |
43 34 272 | Apr 1995 | DE |
29617133 | Jan 1997 | DE |
0 088 341 | Sep 1983 | EP |
0 108 785 | May 1984 | EP |
0 174 162 | Mar 1986 | EP |
0 227 219 | Jul 1987 | EP |
0 237 239 | Sep 1987 | EP |
0 245 872 | Nov 1987 | EP |
0 257 485 | Mar 1988 | EP |
0 639 385 | Feb 1995 | EP |
0 734 721 | Oct 1996 | EP |
0 769 265 | Apr 1997 | EP |
1 061 000 | Oct 2000 | EP |
1 331 020 | Jul 2003 | EP |
1 471 011 | Oct 2004 | EP |
1 442 753 | Feb 2007 | EP |
1 813 293 | Aug 2007 | EP |
1 977 714 | Oct 2008 | EP |
2 444 117 | Apr 2012 | EP |
2 606 930 | Jun 2013 | EP |
2 671 604 | Dec 2013 | EP |
2 731 658 | May 2014 | EP |
2 493 149 | May 1982 | FR |
2 506 162 | Nov 1982 | FR |
2 782 910 | Mar 2000 | FR |
123221 | Feb 1919 | GB |
2 296 182 | Jun 1996 | GB |
2 333 097 | Jul 1999 | GB |
2 387 772 | Oct 2003 | GB |
57-131462 | Aug 1982 | JP |
04-99950 | Feb 1992 | JP |
09-216661 | Aug 1997 | JP |
2000-157630 | Jun 2000 | JP |
2002-234567 | Aug 2002 | JP |
2002-291906 | Oct 2002 | JP |
2005-218649 | Aug 2005 | JP |
2006-182663 | Jul 2006 | JP |
2011-036691 | Feb 2011 | JP |
2011-528647 | Nov 2011 | JP |
2013-520287 | Jun 2013 | JP |
2014-117461 | Jun 2014 | JP |
2 246 321 | Feb 2005 | RU |
WO 8303975 | Nov 1983 | WO |
WO 8505040 | Nov 1985 | WO |
WO 9320806 | Oct 1993 | WO |
WO 9507691 | Mar 1995 | WO |
WO 9635416 | Nov 1996 | WO |
WO 9638136 | Dec 1996 | WO |
WO 199719701 | Jun 1997 | WO |
WO 9812125 | Mar 1998 | WO |
WO 199944665 | Sep 1999 | WO |
WO 200170199 | Sep 2001 | WO |
WO 200205188 | Jan 2002 | WO |
WO 200247581 | Jun 2002 | WO |
WO 200249544 | Jun 2002 | WO |
WO 2003015677 | Feb 2003 | WO |
WO 2003070296 | Aug 2003 | WO |
WO 2004035129 | Apr 2004 | WO |
WO 2004112846 | Dec 2004 | WO |
WO 2005112954 | Dec 2005 | WO |
WO 2005112974 | Dec 2005 | WO |
WO 2006007690 | Jan 2006 | WO |
WO 2006044236 | Apr 2006 | WO |
WO 2006102756 | Oct 2006 | WO |
WO 2007008511 | Jan 2007 | WO |
WO 2007056773 | May 2007 | WO |
WO 2007137056 | Nov 2007 | WO |
WO 2008042285 | Apr 2008 | WO |
WO 2008086631 | Jul 2008 | WO |
WO 2008089196 | Jul 2008 | WO |
WO 2008100950 | Aug 2008 | WO |
WO 2008140807 | Nov 2008 | WO |
WO 2009002474 | Dec 2008 | WO |
WO 2009060322 | May 2009 | WO |
WO 2009117135 | Sep 2009 | WO |
WO 2009123709 | Oct 2009 | WO |
WO 2009136957 | Nov 2009 | WO |
WO 2009153224 | Dec 2009 | WO |
WO 2010002757 | Jan 2010 | WO |
WO 2010002808 | Jan 2010 | WO |
WO 2010011616 | Jan 2010 | WO |
WO 2010034470 | Apr 2010 | WO |
WO 2010039171 | Apr 2010 | WO |
WO 2010062589 | Jun 2010 | WO |
WO 2011028722 | Mar 2011 | WO |
WO 2011053924 | May 2011 | WO |
WO 2011106374 | Sep 2011 | WO |
WO 2011119021 | Sep 2011 | WO |
WO 2012118829 | Sep 2012 | WO |
WO 2012162006 | Nov 2012 | WO |
WO 2013009998 | Jan 2013 | WO |
WO 2013023146 | Feb 2013 | WO |
WO 2012184716 | Dec 2013 | WO |
WO 2013192574 | Dec 2013 | WO |
WO 2014074929 | May 2014 | WO |
WO 2014140949 | Sep 2014 | WO |
WO 14159346 | Oct 2014 | WO |
WO 2015074087 | May 2015 | WO |
WO 2015119940 | Aug 2015 | WO |
WO 2015120336 | Aug 2015 | WO |
WO 2015164129 | Oct 2015 | WO |
WO 2015168677 | Nov 2015 | WO |
WO 2015174953 | Nov 2015 | WO |
WO 2016025775 | Feb 2016 | WO |
WO 2016182822 | Nov 2016 | WO |
WO 2017015047 | Jan 2017 | WO |
WO 2017127364 | Jul 2017 | WO |
WO 2017127365 | Jul 2017 | WO |
WO 2018009653 | Jan 2018 | WO |
WO 2018071717 | Apr 2018 | WO |
WO 2018204206 | Nov 2018 | WO |
WO 2018237090 | Dec 2018 | WO |
WO 2018237122 | Dec 2018 | WO |
WO 2019178560 | Sep 2019 | WO |
WO 2019246472 | Dec 2019 | WO |
WO 2020097366 | May 2020 | WO |
WO 2020251947 | Dec 2020 | WO |
Entry |
---|
Invitation to Pay Additional Search Fees in corresponding International Patent Application No. PCT/US2018/030015, dated Jun. 19, 2018, in 2 pages. |
International Search Report and Written Opinion in corresponding International Patent Application No. PCT/US2018/030015, dated Aug. 27, 2018, in 12 pages. |
Antibiotic Lock Therapy Guidline, Stanford Hospital and Clinics, Pharmacy Department Policies and Procedures, issued Jun. 2011. |
“Small-bore connectors for liquids and gases in healthcare applications—Part : Connectors for intravascular or hypodermic applications,” ISO 80369-7, Corrected version dated Dec. 1, 2016 (50 pages). |
Hospira, “You Work in Neverland,” Lifeshield Product Brochure in 2 pages, Published 2009. |
Baxter Minicap: Photographs of the Baxter Minicap (Sep. 1, 1998) (4 pages). |
Baxter, “Peritoneal Dialysis Patient Connectology,” Product Descriptions in 1 page, downloaded Jul. 1, 2011. |
Beta Cap II Advertisement from Quinton Instrument Co. (Aug. 1981). |
Catheter Connections, “Introducing DualCap,” Product Brochure in 1 page, Copyright 2011. |
Charney, “Baxter Healthcare InterlinkTM IV Access System” in 1 page, from Handbook of Modern Hospital Safety. Published Mar. 1999. |
Clave® Needlefree Connector, icumedial, human connections, 2 page brochure. 2012, M1-1065 Rev. 04. |
Conical Fittings: International Standard, “Conical fittings with 6% (Luer) Taper for Syringes, Needles and certain Other Medical Equipment—Part 2: Lock Fittings”, Ref. No. ISO 594-2:1998. International Organization for Standardization (Sep. 1, 1998) 2nd ed. (16 pages). |
Devine, Redacted version of letter from David A. Divine, Esq. of Lee & Hayes, dated May 16, 2011 (3 pages). |
Devine, Redacted version of letter from David A. Divine, Esq. of Lee & Hayes, dated May 27, 2011 (3 pages). |
Du. Y, et al. Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex, Journal of Biomedical Materials Research Part A, 2006, 216-225. |
Holmer, E. et al. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor XIa, Factor XIIa and kallikrein by antithrombin, Biochem. J. (1981) 193, 395-400. |
Hyprotek, “Port Protek,” Product Brochure in 1 page, downloaded Sep. 19, 2011 from http://www.hyprotek.com/products.html. |
ICU Medical Antimicrobial Microclave, first sold Jan. 21, 2010, p. 1-2. |
Klement, P. et al. Chronic performance of polyurethane catheters covalently coated with ATH complex: A rabbit jugular vein model, Biomaterials, (2006), 27, 5107-5117. |
Menyhay et al., “Disinfection of Needleless Catheter Connectors and Access Ports with Alcohol May Not Prevent Microbial Entry: The Promise of a Novel Antiseptic-Barrier Cap” Infection Control Hospital and Epidemiology, vol. 27, No. 1 (Jan. 2006) (5 pages). |
Otto, Mosby's Pocket Guide to Infusion Therapy. Elsevier Health Sciences, 2004. Pages 65-66. Accessed at: http://books.google.com/books?id=j8T14HwWdS4C&lpg=PP1&pg=PP1#v=onepage&f=false (Year: 2004). |
Photographs of the Baxter Minicap (Sep. 1, 1998) (4 pages). |
Quinton Beta Capp II advertisement, in 3 pages. |
V-Link Luer Activated Device, with VitalShield Protective Coating, 2 page brochure, Baxter Dec. 2009. |
International Preliminary Report on Patentability, re PCT Application No. PCT/US2018/030015, dated Mar. 10, 2020. |
Number | Date | Country | |
---|---|---|---|
20200069931 A1 | Mar 2020 | US |
Number | Date | Country | |
---|---|---|---|
62662149 | Apr 2018 | US | |
62558618 | Sep 2017 | US | |
62520300 | Jun 2017 | US | |
62492887 | May 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2018/030015 | Apr 2018 | US |
Child | 16669303 | US |